<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Chlorpromazine versus placebo for schizophrenia - Adams, CE - 2014 | Cochrane Library</title> <meta content="Chlorpromazine versus placebo for schizophrenia - Adams, CE - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000284.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Chlorpromazine versus placebo for schizophrenia - Adams, CE - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000284.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD000284.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Chlorpromazine versus placebo for schizophrenia" name="citation_title"/> <meta content="Clive E Adams" name="citation_author"/> <meta content="The University of Nottingham" name="citation_author_institution"/> <meta content="clive.adams@nottingham.ac.uk" name="citation_author_email"/> <meta content="George A Awad" name="citation_author"/> <meta content="University of Toronto" name="citation_author_institution"/> <meta content="John Rathbone" name="citation_author"/> <meta content="Bond University" name="citation_author_institution"/> <meta content="Ben Thornley" name="citation_author"/> <meta content="Karla Soares‐Weiser" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD000284.pub3" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/01/06" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000284.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000284.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000284.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antipsychotic Agents [adverse effects, *therapeutic use]; Chlorpromazine [adverse effects, *therapeutic use]; Placebo Effect; Randomized Controlled Trials as Topic; Schizophrenia [*drug therapy, prevention &amp; control]; Secondary Prevention" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000284.pub3&amp;doi=10.1002/14651858.CD000284.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000284.pub3&amp;doi=10.1002/14651858.CD000284.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000284.pub3&amp;doi=10.1002/14651858.CD000284.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000284.pub3&amp;doi=10.1002/14651858.CD000284.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000284.pub3&amp;doi=10.1002/14651858.CD000284.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000284.pub3&amp;doi=10.1002/14651858.CD000284.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000284.pub3&amp;doi=10.1002/14651858.CD000284.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000284.pub3&amp;doi=10.1002/14651858.CD000284.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000284.pub3&amp;doi=10.1002/14651858.CD000284.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000284.pub3&amp;doi=10.1002/14651858.CD000284.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000284.pub3&amp;doi=10.1002/14651858.CD000284.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000284.pub3&amp;doi=10.1002/14651858.CD000284.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000284.pub3&amp;doi=10.1002/14651858.CD000284.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000284.pub3&amp;doi=10.1002/14651858.CD000284.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000284.pub3&amp;doi=10.1002/14651858.CD000284.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000284.pub3&amp;doi=10.1002/14651858.CD000284.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000284.pub3&amp;doi=10.1002/14651858.CD000284.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000284.pub3&amp;doi=10.1002/14651858.CD000284.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000284.pub3&amp;doi=10.1002/14651858.CD000284.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000284.pub3&amp;doi=10.1002/14651858.CD000284.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000284.pub3&amp;doi=10.1002/14651858.CD000284.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000284.pub3&amp;doi=10.1002/14651858.CD000284.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000284.pub3&amp;doi=10.1002/14651858.CD000284.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6zFwvAqw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD000284\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD000284\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000284\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000284\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD000284.pub3",title:"Chlorpromazine versus placebo for schizophrenia",firstPublishedDate:"Jan 6, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000284.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000284.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD000284.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD000284.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000284.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD000284.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD000284.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD000284.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD000284.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD000284.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5055 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD000284.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000284.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000284.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000284.pub3/full#CD000284-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000284.pub3/full#CD000284-sec-0183"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000284.pub3/full#CD000284-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000284.pub3/full#CD000284-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000284.pub3/full#CD000284-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000284.pub3/full#CD000284-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000284.pub3/full#CD000284-sec-0102"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000284.pub3/full#CD000284-sec-0162"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000284.pub3/appendices#CD000284-sec-0194"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/table_n/CD000284StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/table_n/CD000284StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000284.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000284.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000284.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000284.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000284.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD000284.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Chlorpromazine versus placebo for schizophrenia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000284.pub3/information#CD000284-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Clive E Adams</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000284.pub3/information#CD000284-cr-0003">George A Awad</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000284.pub3/information#CD000284-cr-0004">John Rathbone</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000284.pub3/information#CD000284-cr-0005">Ben Thornley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000284.pub3/information#CD000284-cr-0006">Karla Soares‐Weiser</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/information/en#CD000284-sec-0212">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 06 January 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD000284.pub3">https://doi.org/10.1002/14651858.CD000284.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD000284-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000284-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000284-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000284-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000284-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD000284-abs-0001" lang="en"> <section id="CD000284-sec-0001"> <h3 class="title" id="CD000284-sec-0001">Background</h3> <p>Chlorpromazine, formulated in the 1950s, remains a benchmark treatment for people with schizophrenia. </p> </section> <section id="CD000284-sec-0002"> <h3 class="title" id="CD000284-sec-0002">Objectives</h3> <p>To review the effects of chlorpromazine compared with placebo, for the treatment of schizophrenia. </p> </section> <section id="CD000284-sec-0003"> <h3 class="title" id="CD000284-sec-0003">Search methods</h3> <p>We searched the Cochrane Schizophrenia Group’s Trials Register (15 May 2012). We also searched references of all identified studies for further trial citations. We contacted pharmaceutical companies and authors of trials for additional information. </p> </section> <section id="CD000284-sec-0004"> <h3 class="title" id="CD000284-sec-0004">Selection criteria</h3> <p>We included all randomised controlled trials (RCTs) comparing chlorpromazine with placebo for people with schizophrenia and non‐affective serious/chronic mental illness irrespective of mode of diagnosis. Primary outcomes of interest were death, violent behaviours, overall improvement, relapse and satisfaction with care. </p> </section> <section id="CD000284-sec-0005"> <h3 class="title" id="CD000284-sec-0005">Data collection and analysis</h3> <p>We independently inspected citations and abstracts, ordered papers, re‐inspected and quality assessed these. We analysed dichotomous data using risk ratio (RR) and estimated the 95% confidence interval (CI) around this. We excluded continuous data if more than 50% of participants were lost to follow‐up. Where continuous data were included, we analysed this data using mean difference (MD) with a 95% confidence interval. We used a fixed‐effect model. </p> </section> <section id="CD000284-sec-0006"> <h3 class="title" id="CD000284-sec-0006">Main results</h3> <p>We inspected over 1100 electronic records. The review currently includes 315 excluded studies and 55 included studies. The quality of the evidence is very low. We found chlorpromazine reduced the number of participants experiencing a relapse compared with placebo during six months to two years follow‐up (n=512, 3 RCTs, RR 0.65 CI 0.47 to 0.90), but data were heterogeneous. No difference was found in relapse rates in the short, medium or long term over two years, although data were also heterogeneous. We found chlorpromazine provided a global improvement in a person's symptoms and functioning (n=1164, 14 RCTs, RR 0.71 CI 0.58 to 0.86). Fewer people allocated to chlorpromazine left trials early ( n=1831, 27 RCTs, RR 0.64 CI 0.53 to 0.78) compared with placebo. There are many adverse effects. Chlorpromazine is clearly sedating (n=1627, 23 RCTs, RR 2.79 CI 2.25 to 3.45), it increases a person's chances of experiencing acute movement disorders (n=942, 5 RCTs, RR 3.47 CI 1.50 to 8.03) and parkinsonism (n=1468, 15 RCTs, RR 2.11 CI 1.59 to 2.80). Akathisia did not occur more often in the chlorpromazine group than placebo. Chlorpromazine clearly causes a lowering of blood pressure with accompanying dizziness (n=1488, 18 RCTs, RR 2.38 CI 1.74 to 3.25) and considerable weight gain (n=165, 5 RCTs, RR 4.92 CI 2.32 to 10.43). </p> </section> <section id="CD000284-sec-0007"> <h3 class="title" id="CD000284-sec-0007">Authors' conclusions</h3> <p>The results of this review confirm much that clinicians and recipients of care already know but aim to provide quantification to support clinical impression. Chlorpromazine's global position as a 'benchmark' treatment for psychoses is not threatened by the findings of this review. Chlorpromazine, in common use for half a century, is a well‐established but imperfect treatment. Judicious use of this best available evidence should lead to improved evidence‐based decision making by clinicians, carers and patients. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD000284-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000284-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000284-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000284-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000284-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD000284-abs-0005">Hrvatski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD000284-abs-0004" lang="en"> <h3>Chlorpromazine versus placebo for schizophrenia</h3> <p>For previous plain language summary please see <a href="http://03" target="_blank">Appendix 3</a>. </p> <p>People with schizophrenia often hear voices or see things (hallucinations) and have strange beliefs (delusions). The main treatment for these symptoms of schizophrenia is antipsychotic drugs. Chlorpromazine was one of the first drugs discovered to be effective in the treatment of schizophrenia during the 1950s. It remains one of the most commonly used and inexpensive treatments even today. However, being an older drug (‘typical’ or first generation) it also has serious side effects, such as blurred vision, a dry mouth, tremors or uncontrollable shaking, depression, muscle stiffness and restlessness. </p> <p>An update search was carried out in 2012 and the review now includes 55 studies that assess the effects of chlorpromazine in treating schizophrenia compared with no active treatment (‘dummy’ treatment or placebo). Evidence was, in the main, rated by the review authors as low quality. There is some evidence to suggest that chlorpromazine reduces relapse and improves people’s mental health, symptoms and functioning. However, the side effects of chlorpromazine are severe and debilitating. Chlorpromazine causes sleepiness and sedation. It also causes movement disorders (such as tremors and uncontrollable shaking), considerable weight gain and lowering of blood pressure with accompanying dizziness. </p> <p>Chlorpromazine is low‐cost and widely available. Despite its many side effects, chlorpromazine is likely to remain a benchmark drug and one of the most widely used treatments for schizophrenia worldwide. </p> <p>It should be noted that the quality of evidence from the 55 included studies was low and in addition to this, 315 studies were excluded because of flaws in the reporting of information or data and in research design and methods. Larger, better conducted and reported trials should focus on important outcomes such as quality of life, levels of satisfaction, relapse, hospital discharge or admission and number of violent incidents. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD000284-sec-0183" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD000284-sec-0183"></div> <h3 class="title" id="CD000284-sec-0184">Implications for practice</h3> <section id="CD000284-sec-0184"> <section id="CD000284-sec-0185"> <h5 class="title">1. For people with schizophrenia</h5> <p>Many people with schizophrenia and their non‐professional carers recognise psychotic symptoms as phenomena generated by a damaging and pernicious illness and may see the effect of chlorpromazine, as demonstrated within this review, as positive. Others may consider these data as supporting well‐publicised objections to the use of drugs: drugs potent in their ability to cause unpleasant adverse effects, and to potentially erode a person's ability to make informed decisions. </p> </section> <section id="CD000284-sec-0186"> <h5 class="title">2. For clinicians</h5> <p>This review will confirm much that clinicians already know, but it does provide some quantification to support clinical impression. Chlorpromazine is a sedating drug, prone to cause a variety of movement problems and increased weight. Evidence suggests that chlorpromazine reduces relapse and facilitates global improvement. </p> <p>The adverse effect of sedation can, in certain clinical situations (especially in the short term), be a useful adjunct to any antipsychotic properties that chlorpromazine may have. For example, someone acutely disturbed and violent, perhaps because of false beliefs, may well benefit from a certain amount of sedation while the antipsychotic effects of treatment begin to work. </p> <p>Chlorpromazine is a low‐cost and widely available choice for the clinician. Despite its many adverse effects chlorpromazine is likely to remain one of the most widely used treatments for schizophrenia worldwide. </p> </section> <section id="CD000284-sec-0187"> <h5 class="title">3. For managers or policy makers</h5> <p>Chlorpromazine is widely available and inexpensive. It is understandable that it remains one of the essential drugs listed by the WHO for treating people with serious mental illnesses. However, some of chlorpromazine's adverse effects could be expensive in terms of human suffering and cost of treatment. It could, therefore, prove better to use a more costly drug if the latter was equally potent, but had a more favourable adverse effects profile. </p> </section> </section> <h3 class="title" id="CD000284-sec-0188">Implications for research</h3> <section id="CD000284-sec-0188"> <section id="CD000284-sec-0189"> <h5 class="title">1. More trials comparing chlorpromazine with placebo?</h5> <p>Even though chlorpromazine has been used as an antipsychotic drug for decades, there are still a surprisingly small number of well‐conducted randomised, placebo‐controlled trials measuring its efficacy and potential to cause adverse effects. The use of chlorpromazine for millions of people is based on clinical experience rather than the poorly reported trials that involve, in total, only a few thousand participants. Clinicians and researchers are mainly satisfied with the current levels of understanding, and, therefore new studies evaluating chlorpromazine versus placebo will be very rare. However the chlorpromazine story is incomplete. Questions remain regarding the effect of this drug on mental state, long‐term movement disorders and vision. One or more large, methodologically sound randomised, placebo‐controlled trials could help answer these questions. With the advent of new drugs, however, the day for studies comparing chlorpromazine with placebo has passed. </p> </section> <section id="CD000284-sec-0190"> <h5 class="title">2. Placebo‐controlled studies of other treatments</h5> <p>Having shown that chlorpromazine is a benchmark treatment of psychotic symptoms, and knowing that allowing schizophrenia to go untreated may be damaging (<a href="./references#CD000284-bbs2-0376" title="BirchwoodM , McGorryP , JacksonH . Early interventions in schizophrenia. British Journal of Psychiatry1997;170:2‐5. ">Birchwood 1997</a>), the question may well be raised as to whether any placebo‐controlled studies of new antipsychotic drugs are justified. However, the marked level of improvement in the placebo groups in this review would seem to indicate that short‐term studies of those with schizophrenia using a placebo group are justified and would be unlikely to be damaging to those with psychotic illnesses. Using a placebo comparison in the longer term would seem more problematic and difficult to justify. </p> </section> <section id="CD000284-sec-0191"> <h5 class="title">3. Future trials</h5> <p>So much more could have been learnt about the effects of chlorpromazine if the studies in this review had clearly described the method of allocation, the integrity of blinding, especially for the more subjective outcomes, and the reasons for early withdrawal. </p> <p>Concrete and simple outcomes are of interest. For example, clearly reporting improvement, 'number of violent incidents', 'relapse' (giving some description of criteria), 'hospital discharge or admission', and 'presence of delusions or hallucinations' would have been helpful, and simple reporting of levels of satisfaction and quality of life would have been most informative. Chlorpromazine has been in use for decades, yet clinicians still have no trial‐based data indicating how people with schizophrenia perceive the value of this drug in the short, medium and long term. </p> <p>If rating scales are to be employed, a concerted effort should be made to agree on which measures are the most useful. Studies within this review reported on so many scales that, even if results had not been poorly reported, they would have been difficult to synthesise in a clinically meaningful way. </p> <p>Further information on the standardisation of trial reporting can be found in the CONSORT statement (<a href="./references#CD000284-bbs2-0411" title="MoherD , SchulzKF , AltmanD . The CONSORT statement: revised recommendations for improving the quality of reports of parallel‐group randomized trials. JAMA2001;285:1987‐91. ">Moher 2001</a>). </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD000284-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD000284-sec-0022"></div> <div class="table" id="CD000284-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">CHLORPROMAZINE versus PLACEBO for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CHLORPROMAZINE versus PLACEBO for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> hospital and community<br/> <b>Intervention:</b> CHLORPROMAZINE versus PLACEBO </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> CHLORPROMAZINE versus PLACEBO</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b> <br/> Follow‐up: 5 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study specifically reported mortality and there were no deaths in either the chlorpromazine or placebo group. There were no reports of death in any other study. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b> <br/> Follow‐up: 6 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>710 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>461 per 1000</b> <br/> (334 to 639) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.65</b> <br/> (0.47 to 0.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>512<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 trials report this outcome at 0‐8 weeks follow‐up, 3 trials at 6 months to 2 years, and 2 trials 2‐5 years, none showed a significant difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Global state: no overall improvement</b> <br/> (psychiatrist ‐ rated)<br/> Follow‐up: 9 weeks to 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>897 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>637 per 1000</b> <br/> (520 to 772) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.71</b> (0.58 to 0.90) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1164<br/> (14 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>5,6,7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 trials also reported on this outcome at 0‐8 weeks follow‐up and showed a significant result in favour of chlorpromazine. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leaving the study early</b> <br/> Follow‐up: 9 weeks to 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>128 per 1000</b> <br/> (106 to 156) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.64</b> <br/> (0.53 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1831<br/> (27 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 trials reported on this outcome at 0‐8 weeks follow‐up and showed significant results in favour of chlorpromazine. 2 trials reported on this outcome at 6 months to 2 years follow‐up, and 1 trial at 2‐5 years, and there was no significant difference. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with treatment</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Behaviour: deteriorated/ disturbed/un‐cooperative</b> <br/> Follow‐up: 9 weeks to 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>471 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>231 per 1000</b> <br/> (113 to 471) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.49</b> <br/> (0.24 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1040<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>4,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 trials reported on this outcome at 0‐8 weeks follow‐up and found no significant difference. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cost of care</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Serious risk of bias: the study had an unclear risk of bias for random sequence generation, allocation concealment and other bias as the drugs were provided by a pharmaceutical company.<br/> <sup>2</sup> Very serious imprecision: there are very few participants and no events for this outcome.<br/> <sup>3</sup> Serious risk of bias: all studies had an unclear risk of bias for random sequence generation, allocation concealment, blinding of assessors and incomplete data. One also had an unclear risk of other bias as the drugs were provided by a pharmaceutical company.<br/> <sup>4</sup> Very serious inconsistency: there was very high heterogeneity in the pooled results.<br/> <sup>5</sup> Serious risk of bias: one study had a high risk of bias for random sequence generation and in eleven studies it was unclear. Twelve studies had an unclear risk of bias for allocation concealment. Blinding of participants and personnel was unclear in seven studies and blinding of assessors was unclear in twelve. Four studies also had a high risk of other bias as they were funded by industry.<br/> <sup>6</sup> Serious inconsistency: there was high heterogeneity in the pooled results.<br/> <sup>7</sup> Strongly suspected publication bias: the funnel plot suggests that there may be studies without statistically significant effects that have not been included in this analysis.<br/> <sup>8</sup> Very serious risk of bias: twenty four of the studies had an unclear risk of bias for random sequence generation, and all but one for allocation concealment. Twelve studies had an unclear risk of bias for blinding of participants and personnel and in 23 studies it was unclear whether assessors were blinded. Six studies also had a high risk of other bias as they were partly funded by industry.<br/> <sup>9</sup> Serious risk of bias: all studies had an unclear risk of bias for random sequence generation, and all but one for allocation concealment. Three studies had an unclear risk of bias for blinding of participants and personnel, and in all studies it was unclear whether assessors were blinded. Two studies also had a high risk of other bias as they were partly funded by industry. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD000284-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD000284-sec-0023"></div> <section id="CD000284-sec-0024"> <h3 class="title" id="CD000284-sec-0024">Description of the condition</h3> <p>Approximately 24 million people currently suffer from schizophrenia (<a href="./references#CD000284-bbs2-0424" title="WHO: Global Health Statistics Online, 1998. WHO: Global Health Statistics Online, 1998. WWHO: Global Health Statistics Online, 1998. http://w3.whosea.org/en/section1174/section1199/section1567_6744.htm. ">WHO 1998</a>), the majority of whom live in low‐ or middle‐income countries. Chlorpromazine remains one of the most commonly used and inexpensive treatments for people with schizophrenia (<a href="./references#CD000284-bbs2-0412" title="OdejideAO , BanTA . Psychotropic drug prescription pattern in a developing country (Nigeria). The need for an essential psychotherapeutic drug list. International Pharmacopsychiatry1982;17:163‐9. ">Odejide 1982</a>), despite its well‐documented adverse effects and the advent of a new generation of antipsychotic drugs. It is one of the essential drugs listed by the World Health Organization (<a href="./references#CD000284-bbs2-0425" title="WHO: Essential Medicines 13th edition, WHO Model List 2003. http://www.who.int/hac/techguidance/pht/essentialmed/en/. ">WHO 2003</a>). Chlorpromazine is commonly prescribed in India, and in South East Asia, the older generation of antipsychotics are used to treat the majority of people with schizophrenia (<a href="./references#CD000284-bbs2-0381" title="ChongMY , TanCH , FujiiS , YangS , UngvariGS , SiT , et al. Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry and Clinical Neuroscience2004;58:61‐7. ">Chong 2004</a>). In 2003, chlorpromazine was the most frequently prescribed of the first generation 'typical' antipsychotic drugs in the UK at a time when the 'typical' group of antipsychotics accounted for 44% of all antipsychotic prescriptions (<a href="./references#CD000284-bbs2-0414" title="Prescription Pricing Authority: NHS 2003. http://www.ppa.org.uk/index.htm. ">PPA, 2003</a>). </p> </section> <section id="CD000284-sec-0025"> <h3 class="title" id="CD000284-sec-0025">Description of the intervention</h3> <p>Chlorpromazine, a drug developed in 1951 for reducing allergic reactions (an antihistamine) began to be used as part of a cocktail of drugs in order to induce a state of 'artificial hibernation' for surgical procedures (<a href="./references#CD000284-bbs2-0405" title="LaboritH , HuguenardP . no English title available [L'Hibernation artificielle par Moyens pharmacodynamiques et physiques]. Presse Medicale1951;59:1329. ">Laborit 1951</a>). Its ability to reduce psychic stress led researchers to demonstrate its effectiveness for treating certain psychiatric disorders (<a href="./references#CD000284-bbs2-0384" title="DelayJ , DenikerP . [Le traitement des Psychoses par une Methode neuroleptique derivee de l'Hibernotherapie]. CR Congres des Medicins alienistes et neurologistes de France. Luxembourg. 1952:479. ">Delay 1952</a>). Chlorpromazine was hailed as a major discovery for schizophrenia, an illness for which few treatment options existed (<a href="./references#CD000284-bbs2-0382" title="DavisJM , GarverDL . Neuroleptics: clinical use in psychiatry. In: IversonA , IversonB , SnyderC editor(s). Handbook of Psychopharmacology. New York and London: Plenum, 1978. ">Davis 1978</a>). The impact of this drug has been so great, that according to one author, it has been heralded as the second revolution in psychiatry (the first being psychoanalysis) (<a href="./references#CD000284-bbs2-0390" title="GrozierL . The third revolution in psychiatry: fluphenazine decanoate. In: AydFJ editor(s). The Future of Pharmacotherapy: Drug Delivery Systems. Baltimore: International Drug Therapy Newsletter, 1973:97. ">Grozier 1973</a>). Chlorpromazine is the first of many drugs to be classed as a 'neuroleptic' (literally translated: to grasp the nerve), a term coined by two of its first protagonists (<a href="./references#CD000284-bbs2-0384" title="DelayJ , DenikerP . [Le traitement des Psychoses par une Methode neuroleptique derivee de l'Hibernotherapie]. CR Congres des Medicins alienistes et neurologistes de France. Luxembourg. 1952:479. ">Delay 1952</a>). Early trials of chlorpromazine for schizophrenia indicated, that in comparison with placebo, it hastened clinical recovery, facilitated improvements in social functioning and was effective at preventing relapse. </p> </section> <section id="CD000284-sec-0026"> <h3 class="title" id="CD000284-sec-0026">How the intervention might work</h3> <p>The antipsychotic effect of chlorpromazine results from its action on particular areas within specific cells of the brain (<a href="./references#CD000284-bbs2-0419" title="SedvallG , FardeL . Chemical brain anatomy in schizophrenia. Lancet1995;346:743‐9. ">Sedvall 1995</a>). It is thought to affect how receptive these cells are to dopamine. However, chlorpromazine is not specific to one site of action within the body. Consequently, it is known to cause adverse effects ranging from dry mouth, blurred vision and urinary retention as well as restlessness, tremors, facial rigidity, shuffling gait and repetitive movements of the face and/or trunk which can be difficult to reverse (<a href="./references#CD000284-bbs2-0373" title="American Psychiatric Association. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington DC: American Psychiatric Association, 1992. ">APA 1992</a>). Chlorpromazine has also been linked to depressive symptoms that may be caused by the drug itself (neuroleptic dysphoria, <a href="./references#CD000284-bbs2-0375" title="AwadAG . Subjective response to neuroleptics in schizophrenia. Schizophrenia Bulletin1993;19:609‐18. ">Awad 1993</a>). In addition, the use of chlorpromazine has been associated with a potentially fatal disturbance of blood pressure, temperature and muscle control (neuroleptic malignant syndrome, <a href="./references#CD000284-bbs2-0374" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth. Washington DC: American Psychiatric Association, 1994. ">APA 1994</a>). </p> </section> <section id="CD000284-sec-0027"> <h3 class="title" id="CD000284-sec-0027">Why it is important to do this review</h3> <p>There are questions relating to the differential response to drugs between certain groups of people with schizophrenia. For example, there may be differences in the effects of treatment for men and women (<a href="./references#CD000284-bbs2-0393" title="HambrechtT , MaurerK , HafnerH , SartoriusN . Transnational stability of gender differences in schizophrenia? An analysis based on the WHO study on determinants of outcome of severe mental disorders. European Archives of Psychiatry and Clinical Neuroscience1992;242:6‐12. ">Hambrecht 1992</a>; <a href="./references#CD000284-bbs2-0404" title="KendlerKS , WalshD . Gender and schizophrenia. Results of an epidemiologically‐based family study. British Journal of Psychiatry1995;167:184‐92. ">Kendler 1995</a>; <a href="./references#CD000284-bbs2-0420" title="SzymanskiS , LiebermanJA , AlvirJM , MayerhoffD , LoebelA , GeislerS , et al. Gender differences in onset of illness, treatment response, course, and biologic indexes in first‐episode schizophrenic patients. American Journal of Psychiatry1995;152:698‐703. ">Szymanski 1995</a>), for children, adults or the elderly (<a href="./references#CD000284-bbs2-0402" title="KaplanMJ , LazoffM , KellyK , LukinR , GarverDL . Enlargement of cerebral third ventricle in psychotic patients with delayed response to neuroleptics. Biological Psychiatry1990;27:205‐14. ">Kaplan 1990</a>; <a href="./references#CD000284-bbs2-0415" title="RosenJ , BohonS , GershonS . Antipsychotics in the elderly. Acta Psychiatrica Scandinavica Supplement1990;358:170‐5. ">Rosen 1990</a>), or for people who are experiencing their first episode as opposed to those with a longer illness duration (<a href="./references#CD000284-bbs2-0397" title="HillC , KeksNA , JacksonH , KulkarniJ , HannahD , CopolovD , et al. Symptomatic response to antipsychotics differs between recent onset and recurrent chronic schizophrenic patients. Australian and New Zealand Journal of Psychiatry1992;26:417‐22. ">Hill 1992</a>; <a href="./references#CD000284-bbs2-0421" title="SzymanskiSR , CannonTD , GallacherF , ErwinRJ , GurRE . Course of treatment response in first‐episode and chronic schizophrenia. American Journal of Psychiatry1996;153:519‐25. ">Szymanski 1996</a>). When prescribing drugs for schizophrenia dosage is important in order to obtain optimal response with minimal adverse effects (<a href="./references#CD000284-bbs2-0379" title="BolliniP , PampallonaS , OrzaMJ , AdamsME , ChalmersTC . Antipsychotic drugs: is more worse? A meta‐analysis of the published randomized control trials. Psychological Medicine1994;24:307‐16. ">Bollini 1994</a>; <a href="./references#CD000284-bbs2-0401" title="KaneJM , RifkinA , WoernerM , ReardonG , KreismanD , BlumenthalR , et al. High‐dose versus low‐dose strategies in the treatment of schizophrenia. Psychopharmacological Bulletin1985;21:533‐7. ">Kane 1985</a>). There also remains debate about the applicability of research findings to the 'real world' of clinicians (<a href="./references#CD000284-bbs2-0399" title="JenicekM , BertheletteD , BretonJ , CroteauN , LeducN , PineaultR . Content and methods of studies on the prevention and treatment of mental disorders in selected psychiatric journals. Revue d'Epidemiologie et de Sante Publique1990;38:357‐64. ">Jenicek 1990</a>). For example, trials undertaken on highly selected groups of people with schizophrenia may be of very limited use in the 'everyday' situation. We attempted to investigate whether, for the primary outcomes of interest (see: <a href="#CD000284-sec-0029">Methods</a>, <a href="#CD000284-sec-0036">Types of outcome measures</a>), a real difference exists for those with diagnoses of schizophrenia made with operational 'checklists' as opposed to those with less rigorous diagnoses. A final question we posed was whether the effects of chlorpromazine were different between patients treated recently (1990‐2002) to those treated in earlier decades (1951‐1989). </p> <p>New trials often use chlorpromazine as the 'benchmark' or 'control' drug rather than a placebo when a new treatment is being evaluated. The aim of this review is to evaluate this 'benchmark' in comparison to placebo. This is an update of a Cochrane Review first published in 1998, Issue 1 of The Cochrane Database of Systematic Reviews (<a href="./references#CD000284-bbs2-0428" title="ThornleyB , AdamsCE , AwadG . Chlorpromazine versus placebo for those with schizophrenia. Cochrane Database of Systematic Reviews1998, Issue 1. [DOI: 10.1002/14651858] ">Thornley 1998a</a>) and updated in 2003 (<a href="./references#CD000284-bbs2-0429" title="BThornley , JRathbone , CEAdams , GAwad . Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD000284] ">Thornley 2003</a>) and 2007 (<a href="./references#CD000284-bbs2-0427" title="AdamsCE , AwadG , RathboneJ , ThornleyB . Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD000284.pub2] ">Adams 2007</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD000284-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD000284-sec-0028"></div> <p>To review the effects of chlorpromazine compared with placebo, for the treatment of schizophrenia. </p> <p>It was expected that several subgroup analyses could be undertaken within this review (see <a href="#CD000284-sec-0093">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD000284-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD000284-sec-0029"></div> <section id="CD000284-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD000284-sec-0031"> <h4 class="title">Types of studies</h4> <p>We sought all relevant randomised controlled trials. Where a trial was described as 'double blind' but it was implied that the study was randomised, we included these trials in a sensitivity analysis. If their inclusion did not result in a substantive difference, they remained in the analyses. If their inclusion did result in statistically significant differences, we did not add the data from these lower quality studies to the results of the better quality trials, but presented these within a subcategory. We excluded quasi‐randomised studies, such as those allocating by alternate days of the week. </p> </section> <section id="CD000284-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included people with schizophrenia and other types of schizophrenia‐like psychoses (schizophreniform and schizoaffective disorders) however diagnosed, irrespective of age, sex or severity of illness. </p> </section> <section id="CD000284-sec-0033"> <h4 class="title">Types of interventions</h4> <section id="CD000284-sec-0034"> <h5 class="title">1. Chlorpromazine: any dose or mode of administration (oral or by injection)</h5> </section> <section id="CD000284-sec-0035"> <h5 class="title">2. Placebo (active or inactive) or no treatment</h5> </section> </section> <section id="CD000284-sec-0036"> <h4 class="title">Types of outcome measures</h4> <p>We categorised outcomes as short term (zero to eight weeks), medium term (nine weeks to six months) and long term (six months to two years). </p> <section id="CD000284-sec-0037"> <h5 class="title">Primary outcomes</h5> <p>We classified these outcomes as primary outcomes for the 2002 update to help minimise the potential for multiple statistical testing that could be undertaken within sensitivity analyses. We tried to choose these on the grounds of clinical importance and were helped in this by inclusion of a new co‐reviewer, JR, who was not as familiar with the data as the previous authors. We have used the same outcomes but rearranged into new sub‐headings for this 2012 update. </p> <section id="CD000284-sec-0038"> <h6 class="title">1. Death ‐ suicide and natural causes</h6> </section> <section id="CD000284-sec-0039"> <h6 class="title">2. Relapse ‐ as defined by each study</h6> </section> <section id="CD000284-sec-0040"> <h6 class="title">3. Global state</h6> <p>3.1 Overall improvement*</p> </section> <section id="CD000284-sec-0041"> <h6 class="title">4. Leaving the study early</h6> </section> <section id="CD000284-sec-0042"> <h6 class="title">5. Satisfaction with treatment ‐ participant/carer</h6> </section> <section id="CD000284-sec-0043"> <h6 class="title">6. Behaviour</h6> <p>6.1 Specific behaviours (e.g. aggressive or violent behaviour)</p> </section> <section id="CD000284-sec-0044"> <h6 class="title">7. Economic</h6> <p>7.1 Cost of care</p> </section> </section> <section id="CD000284-sec-0045"> <h5 class="title">Secondary outcomes</h5> <section id="CD000284-sec-0046"> <h6 class="title">1. Global state</h6> <p>1.1 Duration of hospital stay<br/> 1.2 Re‐admission<br/> 1.3 Severity of Illness </p> </section> <section id="CD000284-sec-0047"> <h6 class="title">2. Mental state</h6> <p>2.1 General symptoms<br/> 2.2 Specific symptoms<br/> 2.2.1 Positive symptoms (delusions, hallucinations, disordered thinking)<br/> 2.2.2 Negative symptoms (avolition, poor self‐care, blunted affect)<br/> 2.2.3 Mood ‐ depression </p> </section> <section id="CD000284-sec-0048"> <h6 class="title">3. Behaviour</h6> <p>3.1 General behaviour<br/> 3.2 Social functioning<br/> 3.3 Employment status during trial (employed/unemployed)<br/> 3.4 Occurrence of violent incidents (to self, others or property) </p> </section> <section id="CD000284-sec-0049"> <h6 class="title">4. Adverse effects</h6> <p>4.1 General<br/> 4.2 Specific<br/> 4.2.2 Movement disorders (extrapyramidal side effects, specifically tardive dyskinesia and neuroleptic malignant syndrome)<br/> 4.2.3 Sedation<br/> 4.2.4 Dry mouth </p> </section> <section id="CD000284-sec-0050"> <h6 class="title">5. 'Summary of findings' table</h6> <p>We used the GRADE approach to interpret findings (<a href="./references#CD000284-bbs2-0418" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359‐83. ">Schünemann 2008</a>) and GRADE profiler (<a href="http://www.ims.cochrane.org/revman/gradepro" target="_blank">GRADEPRO</a>) to import data from Review Manager 5 (<a href="http://www.ims.cochrane.org/revman" target="_blank">Review Manager</a>) to create a 'Summary of findings' table. These tables provide outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rate as important to patient‐care and decision making. We have selected the following main outcomes for inclusion in the 'Summary of findings' table. </p> <p> <ol id="CD000284-list-0001"> <li> <p>Death ‐ suicide and natural causes</p> </li> <li> <p>Overall improvement</p> </li> <li> <p>Relapse ‐ as defined by each study</p> </li> <li> <p>Leaving the study early</p> </li> <li> <p>Satisfaction with treatment ‐ participant/carer</p> </li> <li> <p>Specific behaviours (e.g. aggressive or violent behaviour)</p> </li> <li> <p>Cost of care</p> </li> </ol> </p> </section> </section> </section> </section> <section id="CD000284-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD000284-sec-0052"> <h4 class="title">Electronic searches</h4> <p>For previous searches please see <a href="./appendices#CD000284-sec-0197">Appendix 2</a>. </p> <section id="CD000284-sec-0053"> <h5 class="title">1. Cochrane Schizophrenia Group Trials Register (May 2012)</h5> <p>The Trials Search Co‐ordinator searched the Cochrane Schizophrenia Group’s Trials Register (15 May 2012).<br/> The Cochrane Schizophrenia Group’s Trials Register is compiled by systematic searches of major databases, handsearches of relevant journals and conference proceedings (see <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html" target="_blank">group module</a>). </p> </section> </section> <section id="CD000284-sec-0054"> <h4 class="title">Searching other resources</h4> <section id="CD000284-sec-0055"> <h5 class="title">1. Reference searching</h5> <p>We inspected the references of all identified studies for further studies.</p> </section> <section id="CD000284-sec-0056"> <h5 class="title">2. Personal contact</h5> <p>For this update, we did not contact the first author of each included study for information regarding unpublished trials. </p> </section> <section id="CD000284-sec-0057"> <h5 class="title">3. Pharmaceutical companies</h5> <p>In previous versions of this review, we contacted pharmaceutical companies for any unpublished and published trials. Approaches have been made to Rhone Poulenc Rorer, the original developers of chlorpromazine, for access to archive material. Dr R.A Pargiter of Hobart, Tasmania very kindly donated a series of reports from May and Baker (the pharmaceutical company which originally produced chlorpromazine) that listed presentations of work relevant to chlorpromazine and schizophrenia, dating from 1955 to 1973. We (BT, CEA and JR) handsearched these for further studies. </p> </section> </section> </section> <section id="CD000284-sec-0058"> <h3 class="title" id="CD000284-sec-0058">Data collection and analysis</h3> <p>Methods used in data collection and analysis for this 2012 update are below; for previous methods please see <a href="./appendices#CD000284-sec-0199">Appendix 3</a>. </p> <section id="CD000284-sec-0059"> <h4 class="title">Selection of studies</h4> <p>For this 2012 update, the Cochrane Schizophrenia group provided Enhance Reviews a database of relevant abstracts; the Enhance Reviews team inspected full articles of the abstracts meeting the inclusion criteria. </p> </section> <section id="CD000284-sec-0060"> <h4 class="title">Data extraction and management</h4> <section id="CD000284-sec-0061"> <h5 class="title">1. Extraction</h5> <p>For this 2012 update, two members of the Enhance Reviews team extracted data from included studies. In addition, Jun Xia (JX) extracted data for all Chinese studies. We extracted data presented only in graphs and figures whenever possible. In the previous versions of the review, when further information was necessary, we contacted authors of studies in order to obtain missing data or for clarification. If studies were multi‐centre, where possible, we extracted data relevant to each component centre separately. </p> </section> <section id="CD000284-sec-0062"> <h5 class="title">2. Management</h5> <section id="CD000284-sec-0063"> <h6 class="title">2.1 Forms</h6> <p>We extracted data onto standard, simple forms, created in a web‐based software (<a href="http://www.systematic-review.ca" target="_blank">www.systematic‐review.ca</a>). </p> </section> <section id="CD000284-sec-0064"> <h6 class="title">2.2 Scale‐derived data</h6> <p>We included continuous data from rating scales only if:<br/> a. the psychometric properties of the measuring instrument have been described in a peer‐reviewed journal (<a href="./references#CD000284-bbs2-0410" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>); and<br/> b. the measuring instrument had not been written or modified by one of the trialists for that particular trial. </p> <p>Ideally, the measuring instrument should either be i. a self‐report or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly; we have noted whether or not this is the case in <a href="#CD000284-sec-0103">Description of studies</a>. </p> </section> <section id="CD000284-sec-0065"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>There are advantages of both endpoint and change data. Change data can remove a component of between‐person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult to measure conditions such as schizophrenia. We decided primarily to use endpoint data, and only use change data if the former were not available. We combined endpoint and change data in the analysis as we used mean differences (MD) rather than standardised mean differences throughout (<a href="./references#CD000284-bbs2-0396" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>, Chapter 9.4.5.2). </p> </section> <section id="CD000284-sec-0066"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we aimed to apply the following standards to all data before inclusion: </p> <p>a) standard deviations (SDs) and means are reported in the paper or obtainable from the authors; </p> <p>b) when a scale starts from the finite number zero, the SD, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution (<a href="./references#CD000284-bbs2-0372" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313:1200. [CHLO020600] ">Altman 1996</a>)); </p> <p>c) if a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS, <a href="./references#CD000284-bbs2-0403" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi‐Health Systems, 1986. ">Kay 1986</a>) which can have values from 30 to 210), we modified the calculation described above to take the scale starting point into account. In these cases skew is present if 2 SD &gt; (S‐S min), where S is the mean score and S min is the minimum score. </p> <p>Endpoint scores on scales often have a finite start and end point and these rules can be applied. We entered skewed endpoint data from studies of fewer than 200 participants in additional tables rather than into an analysis. Skewed data pose less of a problem when looking at the mean if the sample size is large; we entered such endpoint data into syntheses. </p> <p>When continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not, we entered skewed change data into analyses regardless of the size of the study. </p> </section> <section id="CD000284-sec-0067"> <h6 class="title">2.5 Common measure</h6> <p>To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month). </p> </section> <section id="CD000284-sec-0068"> <h6 class="title">2.6 Conversion of continuous to binary</h6> <p>Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS, <a href="./references#CD000284-bbs2-0413" title="OverallJE , GorhamDR . The Brief Psychiatric Rating Scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>) or the PANSS (<a href="./references#CD000284-bbs2-0403" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi‐Health Systems, 1986. ">Kay 1986</a>), this could be considered as a clinically significant response (<a href="./references#CD000284-bbs2-0406" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelRR . What does the PANSS mean?. Schizophrenia Research2005;79(2‐3):231‐8. [PUBMED: 15982856] ">Leucht 2005</a>; <a href="./references#CD000284-bbs2-0407" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of Brief Psychiatric Rating Scale Scores. British Journal of Psychiatry2005;187:366‐71. ">Leucht 2005a</a>). If data based on these thresholds were not available, we used the primary cut‐off presented by the original authors. </p> </section> <section id="CD000284-sec-0069"> <h6 class="title">2.7 Direction of graphs</h6> <p>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for chlorpromazine. </p> </section> </section> </section> <section id="CD000284-sec-0070"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For this 2012 update, two members of the Enhance Reviews team worked independently by using criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD000284-bbs2-0396" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>) to assess trial quality for the new included studies and all previously included studies. This new set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. </p> <p>Where inadequate details of randomisation and other characteristics of trials were provided, we did not contact authors of the studies in order to obtain additional information. </p> <p>We have noted the level of risk of bias in both the text of the review and in the <a href="./full#CD000284-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> <section id="CD000284-sec-0071"> <h4 class="title">Measures of treatment effect</h4> <section id="CD000284-sec-0072"> <h5 class="title">1. Binary data</h5> <p>For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<a href="./references#CD000284-bbs2-0378" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie1999;54(4):405‐11. ">Boissel 1999</a>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<a href="./references#CD000284-bbs2-0383" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25‐28th; Cape Town, South Africa. 2000. ">Deeks 2000</a>). </p> </section> <section id="CD000284-sec-0073"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes we estimated mean difference (MD) between groups. We would prefer not to calculate effect size measures (standardised mean difference (SMD)). However, if scales of very considerable similarity were used, we presumed there was a small difference in measurement, and we would have calculated effect size and transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD000284-sec-0074"> <h4 class="title">Unit of analysis issues</h4> <section id="CD000284-sec-0075"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice), but analysis and pooling of clustered data poses problems. Authors often fail to account for intra‐class correlation in clustered studies, leading to a 'unit of analysis' error (<a href="./references#CD000284-bbs2-0385" title="DivineGW , BrownJT , FrazierLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7(6):623‐9. ">Divine 1992</a>) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<a href="./references#CD000284-bbs2-0377" title="BlandJM . Statistics notes. Trials randomised in clusters. BMJ1997;315:600. ">Bland 1997</a>; <a href="./references#CD000284-bbs2-0391" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). </p> <p>We did not include any cluster trials in this review. If we had, where clustering was not accounted for in primary studies, we would have presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. Where clustering was incorporated into the analysis of primary studies, we would have presented these data as if from a non‐cluster randomised study, but adjusted for the clustering effect. </p> <p>In subsequent versions of this review we will seek to contact first authors of studies to obtain intra‐class correlation coefficients (ICC) for their clustered data and to adjust for this by using accepted methods (<a href="./references#CD000284-bbs2-0391" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). </p> <p>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICC [Design effect=1+(m‐1)*ICC] (<a href="./references#CD000284-bbs2-0386" title="DonnerA , KlarN . Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine2002;21:2971‐80. ">Donner 2002</a>). If the ICC was not reported it was assumed to be 0.1 (<a href="./references#CD000284-bbs2-0423" title="UkoumunneOC , GullifordMC , ChinnS , SterneJAC , BurneyPGJ . Methods for evaluating area‐wide and organistation‐based intervention in health and health care: a systematic review. Health Technology Assessment1999;3(5):1‐75. ">Ukoumunne 1999</a>). </p> <p>If cluster studies have been appropriately analysed taking into account ICCs and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique. </p> </section> <section id="CD000284-sec-0076"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a wash‐out phase. For the same reason cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD000284-bbs2-0388" title="ElbourneD , AltmanDG , HigginsJPT , CurtinaF , WorthingtondHV , VaileA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). As both effects are very likely in severe mental illness, we only used data of the first phase of cross‐over studies. </p> </section> <section id="CD000284-sec-0077"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>Where a study involved more than two treatment arms, if relevant, we presented the additional treatment arms in the comparisons. If data were binary, we simply added these and combined within the two‐by‐two table. If data were continuous, we combined data following the formula in section 7.7.3.8 (Combining groups) of the <i>Cochrane Handbook for Systemic reviews of Interventions</i> (<a href="./references#CD000284-bbs2-0396" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). Where the additional treatment arms were not relevant, we did not reproduce these data. </p> </section> </section> <section id="CD000284-sec-0078"> <h4 class="title">Dealing with missing data</h4> <section id="CD000284-sec-0079"> <h5 class="title">1. Overall loss of credibility</h5> <p>At some degree of loss of follow‐up, data must lose credibility (<a href="./references#CD000284-bbs2-0426" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>). We chose that, for any particular outcome, should more than 50% of data be unaccounted for, we did not reproduce these data or use them within analyses. If, however, more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we marked such data with (*) to indicate that such a result may well be prone to bias. </p> </section> <section id="CD000284-sec-0080"> <h5 class="title">2. Binary</h5> <p>In the case where attrition for a binary outcome was between 0% and 50%, we presented data for the total number of participants randomised for studies that used an intention‐to‐treat (ITT) analysis; where studies did not use an ITT analysis, we presented completer only data. </p> </section> <section id="CD000284-sec-0081"> <h5 class="title">3. Continuous</h5> <section id="CD000284-sec-0082"> <h6 class="title">3.1 Attrition</h6> <p>In the case where attrition for a continuous outcome was between 0% and 50%, and data only from people who completed the study to that point were reported, we presented and used these data. </p> </section> <section id="CD000284-sec-0083"> <h6 class="title">3.2 Standard deviations</h6> <p>If standard deviations (SDs) were not reported, we first tried to obtain the missing values from the authors. If not available, where there are missing measures of variance for continuous data, but an exact standard error (SE) and confidence intervals (CIs) available for group means, and either P value or T value available for differences in mean, we can calculate them according to the rules described in the <i>Cochrane Handbook for Systemic reviews of Interventions</i> (<a href="./references#CD000284-bbs2-0396" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). When only the SE is reported, SDs are calculated by the formula SD=SE * square root (n). Chapters 7.7.3 and 16.1.3 of the <i>Cochrane Handbook for Systemic reviews of Interventions</i> (<a href="./references#CD000284-bbs2-0396" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>) present detailed formulae for estimating SDs from P values, T or F values, CIs, ranges or other statistics. If these formulae do not apply, we would calculate the SDs according to a validated imputation method which is based on the SDs of the other included studies (<a href="./references#CD000284-bbs2-0389" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(7):7‐10. ">Furukawa 2006</a>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study’s outcome and thus to lose information. We did not impute any SDs, if we had we would have examined the validity of the imputations in a sensitivity analysis excluding imputed values. </p> </section> <section id="CD000284-sec-0084"> <h6 class="title">3.3 Last observation carried forward</h6> <p>We anticipated that in some studies the method of last observation carried forward (LOCF) would be employed within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (<a href="./references#CD000284-bbs2-0408" title="LeuchtS , EngelRR , BaumlJ , DavisJM . Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin2007;33(1):183‐91. [PUBMED: 16905632] ">Leucht 2007</a>). Therefore, where LOCF data have been used in the trial, if less than 50% of the data have been assumed, we reproduced these data and indicated that they are the product of LOCF assumptions. </p> </section> </section> </section> <section id="CD000284-sec-0085"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD000284-sec-0086"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations which we had not predicted would arise. When such situations or participant groups arose, we fully discussed these. </p> </section> <section id="CD000284-sec-0087"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise. When such methodological outliers arose, we fully discussed these. </p> </section> <section id="CD000284-sec-0088"> <h5 class="title">3. Statistical heterogeneity</h5> <section id="CD000284-sec-0089"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD000284-sec-0090"> <h6 class="title">3.2 Employing the I<sup>2</sup> statistic </h6> <p>We investigated heterogeneity between studies by considering the I<sup>2</sup> method alongside the Chi<sup>2</sup> P value. The I<sup>2</sup> provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD000284-bbs2-0394" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). The importance of the observed value of I<sup>2</sup> depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. P value from Chi<sup>2</sup> test, or a confidence interval for I<sup>2</sup>). An I<sup>2</sup> estimate greater than or equal to around 50% accompanied by a statistically significant Chi<sup>2</sup> statistic was interpreted as evidence of substantial levels of heterogeneity (<a href="./references#CD000284-bbs2-0396" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). When substantial levels of heterogeneity were found in the primary outcome, we explored reasons for the heterogeneity (<a href="#CD000284-sec-0093">Subgroup analysis and investigation of heterogeneity</a>). If data were heterogeneous we used a random‐effects model. </p> </section> </section> </section> <section id="CD000284-sec-0091"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD000284-bbs2-0387" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315:629‐34. ">Egger 1997</a>). These are described in Section 10 of the <i>Cochrane Handbook for Systemic reviews of Interventions</i> (<a href="./references#CD000284-bbs2-0396" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects. We did not use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar sizes. In other cases, where funnel plots were possible, we sought statistical advice in their interpretation. </p> </section> <section id="CD000284-sec-0092"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument for preference for use of fixed‐effect or random‐effects models. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random‐effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random‐effects model: it puts added weight onto small studies, which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We chose the fixed‐effect model for all analyses. The reader is, however, able to choose to inspect the data using the random‐effects model. </p> </section> <section id="CD000284-sec-0093"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD000284-sec-0094"> <h5 class="title">1. Subgroup analyses ‐ only primary outcomes</h5> <section id="CD000284-sec-0095"> <h6 class="title">1.1 Clinical state, stage or problem</h6> <p>We proposed to undertake this review and provide an overview of the effects of chlorpromazine for people with schizophrenia in general. In addition, however, we tried to report data on subgroups of people in the same clinical state, stage and with similar problems. </p> <p>We also undertook subgroup analyses comparing the results for the following:</p> <p> <ul id="CD000284-list-0002"> <li> <p>men versus women; under 18 years of age versus 18‐65 years old versus older than 65;</p> </li> </ul> <ul id="CD000284-list-0003"> <li> <p>acutely ill people (&lt; one‐month in duration) versus people who have been ill for longer;</p> </li> </ul> <ul id="CD000284-list-0004"> <li> <p>high dose (&gt; 501 mg/day) versus low doses (1‐500 mg/day);</p> </li> </ul> <ul id="CD000284-list-0005"> <li> <p>people diagnosed according to any operational criteria versus those who have not been diagnosed using operational criteria; </p> </li> </ul> <ul id="CD000284-list-0006"> <li> <p>studies published before 1990 versus studies published between 1990 and the present.</p> </li> </ul> </p> </section> </section> <section id="CD000284-sec-0096"> <h5 class="title">2. Investigation of heterogeneity</h5> <p>If inconsistency was high, we have reported this. First, we investigated whether data had been entered correctly. Second, if data were correct, we visually inspected the graph and successively removed outlying to see if homogeneity was restored. </p> <p>When unanticipated clinical or methodological heterogeneity was obvious we simply stated hypotheses regarding these for future reviews or versions of this review. We do not anticipate undertaking analyses relating to these. </p> </section> </section> <section id="CD000284-sec-0097"> <h4 class="title">Sensitivity analysis</h4> <p>We applied sensitivity analyses to the primary outcomes of this review.</p> <section id="CD000284-sec-0098"> <h5 class="title">1. Implication of randomisation</h5> <p>We aimed to include trials in a sensitivity analysis if they were described in some way so as to imply randomisation. For the primary outcomes we included these studies and if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, then we entered all data from these studies. </p> </section> <section id="CD000284-sec-0099"> <h5 class="title">2. Assumptions for lost binary data</h5> <p>Where assumptions had to be made regarding people lost to follow‐up (see <a href="#CD000284-sec-0078">Dealing with missing data</a>), we compared the findings of the primary outcomes when we use our assumption/s and when we used data only from people who completed the study to that point. A sensitivity analysis was undertaken to test how prone results were to change when completer‐only data only were compared to the imputed data using the above assumption. If there was a substantial difference, we reported results and discussed them but continued to employ our assumption. </p> </section> <section id="CD000284-sec-0100"> <h5 class="title">3. Risk of bias</h5> <p>We analysed the effects of excluding trials that were judged to be at high risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available): allocation concealment, blinding and outcome reporting for the meta‐analysis of the primary outcome. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, then we included data from these trials in the analysis. </p> </section> <section id="CD000284-sec-0101"> <h5 class="title">4. Imputed values</h5> <p>Had we included any cluster‐randomised trials, we would have undertaken a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect in cluster‐randomised trials. </p> <p>If we noted substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we did not pool data from the excluded trials with the other trials contributing to the outcome, but presented them separately. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD000284-sec-0102" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD000284-sec-0102"></div> <section id="CD000284-sec-0103"> <h3 class="title">Description of studies</h3> <p>Please see <a href="./references#CD000284-sec-0218" title="">Characteristics of included studies</a> and <a href="./references#CD000284-sec-0219" title="">Characteristics of excluded studies</a>. </p> <section id="CD000284-sec-0104"> <h4 class="title">Results of the search</h4> <p>The original searches in 1995 yielded over 600 references, and after initial appraisal we selected 201 studies for further inspection of the full papers. An additional 50 papers were also identified from the reference lists. We were able to include 45 relevant studies. For the July 2002 update, we found 106 citations and were able to include just one additional study, and four additional reports of already included studies. In addition, May and Baker's files of reports of chlorpromazine studies, kindly supplied by Dr Pargiter of Hobart, Tasmania, were handsearched by BT, CA and JR. These files yielded 37 more records that met the review criteria. Three of these reports were previously unknown studies that could be included. Thirty‐four were excluded. We are very grateful to Dr Pargiter, who kept those files for so long and then, knowing that they could at last be usefully employed, donated them. For the January 2007 update search, we found 317 references from 142 studies. We were able to include one additional study (<a href="./references#CD000284-bbs2-0055" title="Xiong , Hu . A double‐blind comparative study of pheytoin and chlorpromazine in chronic schizophrenics. Medical Journal of Chinese Civil Administration1994;6(4):160‐1. ">Xiong 1994</a>). </p> <p>The May 2012 update search identified a total of 21 new relevant studies. Five trials met the inclusion criteria for this review and there are now 55 studies included in the latest version of this review (see <a href="#CD000284-fig-0001">Figure 1</a>). A total of 315 studies are now excluded. There are no studies awaiting assessment and no ongoing studies have been identified. </p> <div class="figure" id="CD000284-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD000284-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD000284-sec-0105"> <h4 class="title">Included studies</h4> <p>We included 55 studies.</p> <section id="CD000284-sec-0106"> <h5 class="title">1. Methods</h5> <p>Four included studies were cross‐over trials (<a href="./references#CD000284-bbs2-0002" title="BakerJP . A controlled trial of ethylcrotonylurea. British Journal of Psychiatry1959;105:852‐62. ">Baker 1959</a>; <a href="./references#CD000284-bbs2-0033" title="LetemendiaF , HarrisAD . Chlorpromazine and the untreated chronic schizophrenic: a long‐term trial. British Journal of Psychiatry1967;113:950‐8. ">Letemendia 1967</a>; <a href="./references#CD000284-bbs2-0034" title="NishikawaT , TsudaA , TanakaM , KogaI , UchidaY . Prophylactic effect of neuroleptics in symptom‐free schizophrenics. Psychopharmacology1982;77:301‐4. ">Nishikawa 1982</a>; <a href="./references#CD000284-bbs2-0046" title="ShepherdM , WattDC . A controlled clinical study of chlorpromazine and reserpine. Journal of Neurology, Neurosurgery and Psychiatry1956;19:232‐5. ">Shepherd 1956</a>), two had a factorial design (<a href="./references#CD000284-bbs2-0027" title="HamiltonM , SmithA , LapidusHR , CadoganEP . A controlled trial of Thiopropazate Dihydrochloride (Dartalan), Chlorpromazine and occupational therapy in chronic schizophrenics. British Journal of Psychiatry1960;106:40‐55. ">Hamilton 1960</a>; <a href="./references#CD000284-bbs2-0030" title="GoldbergS , SchoolerN , HogartyG , RoperM . Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy. Archives of General Psychiatry1977;34:171‐84. HogartyG , GoldbergS . Drug and sociotherapy in the aftercare of schizophrenic patients. One‐year relapse rates. Archives of General Psychiatry1973;28:54‐64. HogartyG , GoldbergS , SchoolerN . Drug and sociotherapy in the aftercare of schizophrenic patients. III. Adjustment of non relapsed patients. Archives of General Psychiatry1974;31:609‐18. HogartyG , GoldbergS , SchoolerN , UlrichR . Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two‐year relapse rates. Archives of General Psychiatry1974;31:603‐8. HogartyG , UlrichR . Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients. Archives of General Psychiatry1977;34:297‐301. HogartyGE , MunetzMR . Pharmacogenic depression among outpatient schizophrenic patients ‐ a failure to substantiate. Journal of Clinical Psychopharmacology1984;4:17‐24. ">Hogarty 1973</a>), and the remainder were parallel studies. All studies were either stated to be randomised or implied randomisation. </p> </section> <section id="CD000284-sec-0107"> <h5 class="title">2. Length of trials</h5> <p>The most common study length was six to 12 weeks but the range was considerable with two trials being just over 24 hours in duration, whilst the two longest were over a period of three years. </p> </section> <section id="CD000284-sec-0108"> <h5 class="title">3. Participants</h5> <p>It was reported in all trials that the participants suffered from schizophrenia (with the exception of <a href="./references#CD000284-bbs2-0052" title="VaughanGF , LeibermanDM , CookLC . Chlorpromazine in psychiatry. Lancet1955;1:1083‐7. ">Vaughan 1955</a> who randomised people with mental illnesses who were 'chronic and intractable' with motor restlessness, psychomotor agitation, and excitement and <a href="./references#CD000284-bbs2-0028" title="HankoffLD , RudorferL , PaleyHM . A reference study of ataraxics. A two‐week double blind outpatient evaluation. Journal of New Drugs1962;2:173‐8. [MEDLINE: 13904352] ">Hankoff 1962</a> who did not clearly state the diagnoses but included psychiatric outpatients who were 'schizophrenic and non‐schizophrenic', with the majority having schizophrenia). Only 14 of the 55 trials described the diagnostic criteria used, or the symptoms required for people to be included. Otherwise, entry to most included studies was on a clinical diagnosis of schizophrenia. A total of 5506 participants are now included in this review. </p> </section> <section id="CD000284-sec-0109"> <h5 class="title">4. Setting</h5> <p>Most studies were hospital‐based with only a few of the studies being undertaken in the community. </p> </section> <section id="CD000284-sec-0110"> <h5 class="title">5. Study size</h5> <p>The mean number of participants was 99, ranging from 21 (<a href="./references#CD000284-bbs2-0035" title="PayneP . A comparison of trifluopromazine, chlorpromazine and a placebo in twenty‐one chronic schizophrenic patients. Manitoba Medical Review1960:196‐8. ">Payne 1960</a>) to 838 (<a href="./references#CD000284-bbs2-0037" title="CraneGE . Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs. Agressologie1968;2:209‐18. DeLongSL . Incidence and significance of chlorpromazine‐induced eye changes. Diseases of the Nervous System1968;29:19‐22. GardosG , ColeJO , LaBrieRA . A 12‐year follow‐up study of chronic schizophrenics. Hospital and Community Psychiatry1982;33:983‐4. MandelA , GrossM . Agranulocyctosis and phenothiazines. Diseases of the Nervous System1968;29:32‐6. PrienR , ColeJO . High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health ‐ psychopharmacology research branch collaborative study group. Archives of General Psychiatry1968;18:482‐95. PrienR , DeLongS , ColeJ , LevineJ . Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study. Archives of General Psychiatry1970;23:464‐8. PrienRF , ColeJO , BelkinNF . Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. British Journal of Psychiatry1968;115:679‐86. PrienRF , LevineJ , ColeJO . Indications for high dose chlorpromazine therapy in chronic schizophrenia. Diseases of the Nervous System1970;31:739‐45. ">Prien 1968</a>). </p> </section> <section id="CD000284-sec-0111"> <h5 class="title">6. Intervention</h5> <p>6.1 Chlorpromazine: The doses of chlorpromazine in these studies ranged from 25 mg/day (<a href="./references#CD000284-bbs2-0042" title="ReschkeRW . Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia. Diseases of the Nervous System1974;35:112‐5. ">Reschke 1974</a>) to 2400 mg/day (<a href="./references#CD000284-bbs2-0019" title="DeanEF , BukerS . Schizophrenia treated with and without chlorpromazine. Rocky Mountain Medical Journal1958;55:47‐50. ">Dean 1958</a>). The mean dose was 574 mg/day (SD 446). </p> <p>6.2 Placebo: All trials compared chlorpromazine with placebo or no treatment. <a href="./references#CD000284-bbs2-0032" title="KurlandAA , HanlonTE , TatomMH , OtaKY , SimopoulosAL . The comparative effectiveness of six phenothiazine compounds, phenobarbital and inert placebo in the treatment of acutely ill patients: global measures of severity of illness. Journal of Nervous and Mental Disease1961;133:1‐18. KurlandAA , HanlonTE , TatomMH , SimopoulosAL . Comparative studies of the phenothiazine tranquilizers: methodological and logistical considerations. Journal of Nervous and Mental Disease1961;132:61‐74. KurlandAA , NilssonGL , HanlonTE . Pre‐admission drug treatment of state psychiatric hospital patients. American Journal of Psychiatry1959;115:1028‐9. KurlandAA , SutherlandGF . The phenothiazine tranquilizers ‐ their neurological complications and significance. Psychosomatics1960;1:192‐4. ">Kurland 1961</a> used a 'positive' placebo (phenobarbital) and a 'negative' placebo, the results of which were combined in this review. <a href="./references#CD000284-bbs2-0009" title="ClarkML , HuberWK , KyriakopoulosAA , RayTS , ColmoreJP , RamseyHR . Evaluation of trifluperidol in chronic schizophrenia. Psychopharmacologia1968;12:193‐203. ">Clark 1968a</a> randomised participants to placebo and a no‐drug group, which were also combined in this review. <a href="./references#CD000284-bbs2-0037" title="CraneGE . Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs. Agressologie1968;2:209‐18. DeLongSL . Incidence and significance of chlorpromazine‐induced eye changes. Diseases of the Nervous System1968;29:19‐22. GardosG , ColeJO , LaBrieRA . A 12‐year follow‐up study of chronic schizophrenics. Hospital and Community Psychiatry1982;33:983‐4. MandelA , GrossM . Agranulocyctosis and phenothiazines. Diseases of the Nervous System1968;29:32‐6. PrienR , ColeJO . High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health ‐ psychopharmacology research branch collaborative study group. Archives of General Psychiatry1968;18:482‐95. PrienR , DeLongS , ColeJ , LevineJ . Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study. Archives of General Psychiatry1970;23:464‐8. PrienRF , ColeJO , BelkinNF . Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. British Journal of Psychiatry1968;115:679‐86. PrienRF , LevineJ , ColeJO . Indications for high dose chlorpromazine therapy in chronic schizophrenia. Diseases of the Nervous System1970;31:739‐45. ">Prien 1968</a>, however, randomised to a placebo group and a 'routine conventional hospital treatment' group. These groups were not combined because the latter had the opportunity to receive any medication that the treating physicians felt appropriate (presumably including chlorpromazine). <a href="./references#CD000284-bbs2-0037" title="CraneGE . Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs. Agressologie1968;2:209‐18. DeLongSL . Incidence and significance of chlorpromazine‐induced eye changes. Diseases of the Nervous System1968;29:19‐22. GardosG , ColeJO , LaBrieRA . A 12‐year follow‐up study of chronic schizophrenics. Hospital and Community Psychiatry1982;33:983‐4. MandelA , GrossM . Agranulocyctosis and phenothiazines. Diseases of the Nervous System1968;29:32‐6. PrienR , ColeJO . High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health ‐ psychopharmacology research branch collaborative study group. Archives of General Psychiatry1968;18:482‐95. PrienR , DeLongS , ColeJ , LevineJ . Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study. Archives of General Psychiatry1970;23:464‐8. PrienRF , ColeJO , BelkinNF . Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. British Journal of Psychiatry1968;115:679‐86. PrienRF , LevineJ , ColeJO . Indications for high dose chlorpromazine therapy in chronic schizophrenia. Diseases of the Nervous System1970;31:739‐45. ">Prien 1968</a> also included two arms, one with lower doses and the other with higher doses. We pooled data from these arms in the main analysis and conducted subgroup analyses. </p> <p>6.3 Other drug treatment arms: Thirty‐eight of the trials also included at least one more drug treatment arm in addition to placebo and chlorpromazine. Data were not included from these treatment arms. </p> </section> <section id="CD000284-sec-0112"> <h5 class="title">7. Outcomes</h5> <p>The following outcomes were reported by the included studies: death, relapse, global impression, mental state, behaviour, leaving the study early and adverse effects. None of the included studies attempted to quantify levels of satisfaction, or quality of life and there is no evidence of any direct economic evaluation of chlorpromazine. Most outcomes analysed were dichotomous, and presented as such, or were ordinal data that could be dichotomised. </p> <section id="CD000284-sec-0113"> <h6 class="title">7.1 Outcome scales</h6> <p>The following scales provided continuous data for the analysis.</p> <section id="CD000284-sec-0114"> <p><b>7.1.2 Mental state</b></p> <p>i. Brief Psychiatric Rating Scale (<a href="./references#CD000284-bbs2-0413" title="OverallJE , GorhamDR . The Brief Psychiatric Rating Scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>)<br/> A brief rating scale used to assess the severity of a range of psychiatric symptoms, including psychotic symptoms. The original scale has 16 items, but a revised 18‐item scale is commonly used. Each item is defined on a seven‐point scale varying from 'not present' to 'extremely severe', scoring from zero to six or one to seven. Scores can range from zero to 126, with high scores indicating more severe symptoms. <a href="./references#CD000284-bbs2-0051" title="TetreaultL . Comparative study of two drugs and a placebo in chronic schizophrenia [Etude comparative de deux medicaments et d'un placebo chez le schizophrene chronique]. Actualites Pharmacologiques1969;22:221‐8. TetreaultL , BordeleauJM , GauthierR , VulpeM , LapointeL . Comparative study of TPS‐23, chlorpromazine and placebo in chronic schizophrenic patients. Diseases of the Nervous System1969;30(2):74‐84. ">Tetreault 1969</a> reported data from this scale. </p> <p>ii. Global impression<br/> 4.7.2.1 Clinical Global Impression (<a href="./references#CD000284-bbs2-0392" title="GuyW . Early Clinical Drug Evaluation (ECDEU) Assessment Manual for Psychopharmacology. Washington DC: National Institute of Mental Health, 1976. [Publication No.76‐338] ">Guy 1976</a>)<br/> A rating instrument commonly used in studies on schizophrenia that enables clinicians to quantify severity of illness and overall clinical improvement. A seven‐point scoring system is usually used with low scores indicating decreased severity and/or greater recovery. <a href="./references#CD000284-bbs2-0005" title="BorisonRL , DiamondBI , DrenAT . Does sigma receptor antagonism predict clinical antipsychotic efficacy?. Psychopharmacology Bulletin1991;27:103‐6. BorisonRL , DrenAT , DiamondBI . Sigma receptor antagonism and antipsychotic actions in schizophrenic patients. European Journal of Pharmacology1990;183:23. ">Borison 1991</a> reported data from this scale. </p> </section> <section id="CD000284-sec-0115"> <p><b>7.1.3 Behaviour</b></p> <p>i. Modified Rosenthal Rating Scale (<a href="./references#CD000284-bbs2-0416" title="RosenthalD . Ratings of disturbance in various categories of behavior during hospitalization. In: RosenthalD editor(s). The Gerain Quadruplets: a Study of Heredity and Environment in Schizophrenia. New York: Basic Books, 1963. ">Rosenthal 1963</a>)<br/> A scale for nurses to rate the behaviour of psychiatric patients. Lower scores indicate improved behaviour. <a href="./references#CD000284-bbs2-0051" title="TetreaultL . Comparative study of two drugs and a placebo in chronic schizophrenia [Etude comparative de deux medicaments et d'un placebo chez le schizophrene chronique]. Actualites Pharmacologiques1969;22:221‐8. TetreaultL , BordeleauJM , GauthierR , VulpeM , LapointeL . Comparative study of TPS‐23, chlorpromazine and placebo in chronic schizophrenic patients. Diseases of the Nervous System1969;30(2):74‐84. ">Tetreault 1969</a> reported data from this scale. </p> <p>ii. Parkside Behaviour Rating Scale (<a href="./references#CD000284-bbs2-0305" title="SchmidtKE . Combined treatment with chlorpromazine and reserpine: an attempt at quantitative assessments in chronic schizophrenic patients. British Journal of Psychiatry1957;103:200‐8. ">Schmidt 1957</a>)<br/> A rating scale in which six behavioural characteristics are rated on a five‐point scale. The worst possible behaviour would carry a rating of six points, as against a maximum of 30 points for unproblematic behaviour. <a href="./references#CD000284-bbs2-0002" title="BakerJP . A controlled trial of ethylcrotonylurea. British Journal of Psychiatry1959;105:852‐62. ">Baker 1959</a> reported data from this scale. </p> <p>iii. Fergus Falls rating scale (<a href="./references#CD000284-bbs2-0409" title="LuceroRJ , MeyerBT . A behavior rating scale suitable for use in mental hospitals. Journal of Clinical Psychology1951;7:250‐4. [DOI: 10.1002/1097] ">Lucero 1951</a>)<br/> The L‐M Fergus Falls Behavior Rating Scale is a method of rating the behaviour of patients in mental hospitals, which measures 11 aspects of behaviour, and the changes in one patient over a length of time. <a href="./references#CD000284-bbs2-0039" title="RamuMG , ChaturvediDD , VenkataramBS , ShankaraMR , LeelavathyS , JanakiramiahN , et al. A DOUBLE BLIND controlled study on the role of brahmyadiyoga and tagara in jirnomada (chronic schizophrenia). Ayurvedic Management of Unmada (Schizophrenia). New Delhi: Central Council for Research in Ayurveda &amp; Siddha, 1999:77‐88. ">Ramu 1999a</a> reported data from this scale. </p> </section> <section id="CD000284-sec-0116"> <p><b>7.1.4. Adverse effects</b></p> <p>i. Extrapyramidal Bilan scale (<a href="./references#CD000284-bbs2-0339" title="TetreaultL , BordeleauJM , AlbertJM , RajotteP . Comparative study of fluphenazine ethanate, fluphenazine bichlorhydrate and placebos in chronic schizophrenics [Etude comparative de l'enanthate de fluphenazine, du bichlorhydrate de fluphenazine et du placebo chez le schizophrene chronique]. Canadian Psychiatric Association Journal1969;14(2):191‐8. [MEDLINE: 69202908] ">Tetreault 1969a</a>)<br/> A nine‐item rating scale for use by neurologists, to measure severity of symptoms such as facial mask, tremor, rigidity, akathisia, dystonia, dyskinesia and others. Each item can be scored from zero to three, such that the overall score can range from zero (no symptoms) to a possible 27 (severe symptoms of all types). <a href="./references#CD000284-bbs2-0051" title="TetreaultL . Comparative study of two drugs and a placebo in chronic schizophrenia [Etude comparative de deux medicaments et d'un placebo chez le schizophrene chronique]. Actualites Pharmacologiques1969;22:221‐8. TetreaultL , BordeleauJM , GauthierR , VulpeM , LapointeL . Comparative study of TPS‐23, chlorpromazine and placebo in chronic schizophrenic patients. Diseases of the Nervous System1969;30(2):74‐84. ">Tetreault 1969</a> reported data from this scale. </p> </section> </section> </section> </section> <section id="CD000284-sec-0117"> <h4 class="title">Excluded studies</h4> <p>We have now excluded 315 studies. The studies listed in the 'Excluded studies' section had to be inspected in hard copy in order to make the final decision. Nearly half were not randomised, did not imply randomisation or did not describe the allocation procedure used. In several studies, participants were not suffering from schizophrenia. Another sizeable proportion of the trials did not compare chlorpromazine with placebo, but in combination with other treatments. A few were chlorpromazine withdrawal studies investigating the effects of instigation of treatment, which are not relevant to this review. We will include these withdrawal studies in a later review. Eighty‐eight studies had no usable outcomes. Either data did not have clear clinical implications, for example EEG recordings, or genuinely relevant clinical data were not adequately reported. Frequently the numbers of participants in each group were not specified, means or standard deviations were not given or data were not reported from individual arms of cross‐over studies. </p> <section id="CD000284-sec-0118"> <h5 class="title">Awaiting assessment</h5> <p>No studies are currently awaiting assessment.</p> </section> <section id="CD000284-sec-0119"> <h5 class="title">Ongoing studies</h5> <p>We identified no ongoing studies.</p> </section> </section> </section> <section id="CD000284-sec-0120"> <h3 class="title">Risk of bias in included studies</h3> <p>Please also see <a href="#CD000284-fig-0002">Figure 2</a> and <a href="#CD000284-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD000284-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD000284-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD000284-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD000284-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> </div> <section id="CD000284-sec-0121"> <h4 class="title">Allocation</h4> <p>Only four studies described the methods used to generate random allocation. Two studies (<a href="./references#CD000284-bbs2-0029" title="HineFR . Chlorpromazine in schizophrenic withdrawal and in the withdrawn schizophrenic. Journal of Nervous and Mental Diseases1958;127:220‐7. ">Hine 1958</a>; <a href="./references#CD000284-bbs2-0033" title="LetemendiaF , HarrisAD . Chlorpromazine and the untreated chronic schizophrenic: a long‐term trial. British Journal of Psychiatry1967;113:950‐8. ">Letemendia 1967</a>) randomised by the toss of a coin, and two used tables of random numbers (<a href="./references#CD000284-bbs2-0026" title="HamillWT , FontanaAF . The immediate effects of chlorpromazine in newly admitted schizophrenic patients. American Journal of Psychiatry1975;132:1023‐6. ">Hamill 1975</a>; <a href="./references#CD000284-bbs2-0339" title="TetreaultL , BordeleauJM , AlbertJM , RajotteP . Comparative study of fluphenazine ethanate, fluphenazine bichlorhydrate and placebos in chronic schizophrenics [Etude comparative de l'enanthate de fluphenazine, du bichlorhydrate de fluphenazine et du placebo chez le schizophrene chronique]. Canadian Psychiatric Association Journal1969;14(2):191‐8. [MEDLINE: 69202908] ">Tetreault 1969a</a>). Two studies (<a href="./references#CD000284-bbs2-0017" title="ColeJO , GoldbergSC , Klerman GL National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group. Phenothiazine treatment in acute schizophrenia. Archives of General Psychiatry1964;10:246‐61. GoldbergS , KlermanG , ColeJ . Changes in schizophrenic psychopathology and ward behaviour as a function of phenothiazine treatment. British Journal of Psychiatry1965;111:120‐33. GoldbergSC , MattssonNB . Schizophrenic subtypes defined by response to drugs and placebo. Diseases of the Nervous System1968;29:153‐8. ">Cole 1964</a>; <a href="./references#CD000284-bbs2-0025" title="HallRA , DunlapDJ . A study of chlorpromazine: methodology and results with chronic semi‐disturbed schizophrenics. Journal of Nervous and Mental Disease1955;122:301‐14. HollisterLE , HallRA . Phenothiazine derivatives and morphologic changes in the liver. American Journal of Psychiatry1966;123:211‐2. ">Hall 1955</a>) described some form of allocation concealment (sealed envelopes). For the other 53 studies, readers are given little assurance that bias was minimised during the allocation procedure, yet 24 (24/53, 45%) reported that the participants allocated to each treatment group were very similar. One study, <a href="./references#CD000284-bbs2-0018" title="CooperSJ , ButlerA , TweedJ , WelchCP . Zotepine in the treatment of chronic schizophrenia. 10th ECNP (European College of Neuropsychopharmacology) Congress. Vienna, Austria. Vienna, Austria, September 13‐17, 1997. CooperSJ , RaniwallaJ , WelchC . Zotepine in acute exacerbation of schizophrenia: a comparison versus chlorpromazine and placebo. XXth Collegium Internationale Neuro‐psychopharmacologicum. Melbourne, Australia. Melbourne, Australia, 1996. CooperSJ , TweedJ , RaniwallaJ , ButlerA , WelchC . A placebo controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatrica Scandinavica2000;101(3):218‐25. [MEDLINE: 20184895] CooperSJ , TweedJ , RaniwallaJ , WelchC . A placebo‐controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Unpublished manuscript1996. CooperSJ , WelchCP . A comparison of zotepine and chlorpromazine on BPRS subscores. 10th ECNP (European College of Neuropsychopharmacology) Congress. Vienna, Austria. Vienna, Austria, September 13‐17, 1997. ">Cooper 2000</a>, reported that participants were randomly assigned in blocks of six and <a href="./references#CD000284-bbs2-0054" title="WeckowiczTE , WardT . Clinical trial of RO 5‐0690 and chlorpromazine on disturbed chronic schizophrenic patients. Diseases of the Nervous System1960;21:527‐8. [MEDLINE: 13783681] ">Weckowicz 1960</a> reported that participants were divided into three matched groups. For the remaining studies it is improbable that such equal numbers could have been obtained unless block randomisation was used, yet 24 out of 53 studies (45%) had exactly the same numbers in the chlorpromazine and placebo groups. </p> </section> <section id="CD000284-sec-0122"> <h4 class="title">Blinding</h4> <p>Thirty‐five studies had a low risk of bias for performance bias and described the methods used to ensure blinding of participants and personnel. Twenty studies had an unclear risk of bias. Nine studies stated that outcome assessors were blinded and were rated a low risk of bias, the remainder had an unclear risk of bias. Two studies (<a href="./references#CD000284-bbs2-0023" title="GrygierP , WatersMA . Chlorpromazine used with an intensive occupational therapy program. A.M.A. Archives of Neurology and Psychiatry1958;79:697‐705. ">Grygier 1958</a>; <a href="./references#CD000284-bbs2-0025" title="HallRA , DunlapDJ . A study of chlorpromazine: methodology and results with chronic semi‐disturbed schizophrenics. Journal of Nervous and Mental Disease1955;122:301‐14. HollisterLE , HallRA . Phenothiazine derivatives and morphologic changes in the liver. American Journal of Psychiatry1966;123:211‐2. ">Hall 1955</a>) tested how successful their attempts at blinding were. Three studies (<a href="./references#CD000284-bbs2-0012" title="ClarkM , DubowskiK , ColmoreJ . The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clinical Pharmacology and Therapeutics1970;11:883‐9. ClarkM , RamseyH , RahhalD , SerafetinidesE , WoodF , CostiloeJ . Chlorpromazine in chronic schizophrenia. The effect of age and hospitalization on behavioral dose‐response relationships. Archives of General Psychiatry1972;27:479‐83. ClarkML , RamseyHR , RaglandRE , RahhalDK , SerafetinidesEA , CostiloeJP . Chlorpromazine in chronic schizophrenia ‐ behavioral dose‐response relationships. Psychopharmacologia1970;18:260‐70. SerafetinidesEA , WillisD , ClarkML . EEG dose‐response relationships of chlorpromazine in chronic schizophrenia: the effects on the various rhythms and on alpha blocking. Biological Psychiatry1972;4:251‐6. ">Clark 1970b</a>; <a href="./references#CD000284-bbs2-0026" title="HamillWT , FontanaAF . The immediate effects of chlorpromazine in newly admitted schizophrenic patients. American Journal of Psychiatry1975;132:1023‐6. ">Hamill 1975</a>; <a href="./references#CD000284-bbs2-0047" title="SimonW , WirtAL , WirtRD , HalloranAV . Long‐term follow‐up study of schizophrenic patients. Archives of General Psychiatry1965;12:510‐5. SimonW , WirtR , WirtA , HalloranA , HinckleyR , LundJ , et al. A controlled study of the short‐term differential treatment of schizophrenia. American Journal of Psychiatry1958;114:1077‐86. ">Simon 1958</a>) gave no indication that blinding had been attempted. </p> </section> <section id="CD000284-sec-0123"> <h4 class="title">Incomplete outcome data</h4> <p>Twenty‐nine studies were rated as low risk of bias for incomplete outcome data and 19 studies had an unclear risk of bias. Seven studies were rated as having a high risk of bias. </p> </section> <section id="CD000284-sec-0124"> <h4 class="title">Selective reporting</h4> <p>Only five studies had a low risk of bias for selective reporting. Three studies had an unclear risk of bias and 47 of the studies were rated as high risk of bias for selective reporting. </p> </section> <section id="CD000284-sec-0125"> <h4 class="title">Other potential sources of bias</h4> <p>Eight trials were subject to other biases as they were either partly or fully funded by the pharmaceutical industry; in <a href="./references#CD000284-bbs2-0005" title="BorisonRL , DiamondBI , DrenAT . Does sigma receptor antagonism predict clinical antipsychotic efficacy?. Psychopharmacology Bulletin1991;27:103‐6. BorisonRL , DrenAT , DiamondBI . Sigma receptor antagonism and antipsychotic actions in schizophrenic patients. European Journal of Pharmacology1990;183:23. ">Borison 1991</a> two of the trialists are in prison for research fraud. Twelve studies were of low risk of bias for other potential sources of bias and the remainder had an unclear risk of bias. </p> </section> </section> <section id="CD000284-sec-0126"> <h3 class="title" id="CD000284-sec-0126">Effects of interventions</h3> <p>See: <a href="./full#CD000284-tbl-0001"><b>Summary of findings for the main comparison</b> CHLORPROMAZINE versus PLACEBO for schizophrenia</a> </p> <p>We used risk ratios (RR) for dichotomous data and mean differences (MD) for continuous data, with their respective 95% confidence intervals (CIs) throughout. </p> <section id="CD000284-sec-0127"> <h4 class="title">1. Comparison: CHLORPROMAZINE versus PLACEBO</h4> <p>We categorised outcomes as short term (up to eight weeks), medium term (nine weeks to six months) and long term (six months to two years). </p> <section id="CD000284-sec-0128"> <h5 class="title">1.1 Death</h5> <p>We found only one small trial (n=14) that specifically reported mortality (<a href="./references#CD000284-bbs2-0002" title="BakerJP . A controlled trial of ethylcrotonylurea. British Journal of Psychiatry1959;105:852‐62. ">Baker 1959</a>); there were no deaths in either the chlorpromazine or placebo group (<a href="./references#CD000284-fig-0004" title="">Analysis 1.1</a>). We found no reports of death in any study and currently over 5506 people have been included in trials relating to this review (of which 1741 were given chlorpromazine). </p> </section> <section id="CD000284-sec-0129"> <h5 class="title">1.2 Relapse</h5> <p>We found short‐term (n=74, 2 RCTs) and medium‐term (n=809, 4 RCTs) data did not show a significant difference in rates of relapse (<a href="./references#CD000284-fig-0005" title="">Analysis 1.2</a>), but with significant heterogeneity (I<sup>2</sup>=78% and 96%, respectively). Removing the studies with results that were causing this heterogeneity, as judged by visual inspection (<a href="./references#CD000284-bbs2-0037" title="CraneGE . Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs. Agressologie1968;2:209‐18. DeLongSL . Incidence and significance of chlorpromazine‐induced eye changes. Diseases of the Nervous System1968;29:19‐22. GardosG , ColeJO , LaBrieRA . A 12‐year follow‐up study of chronic schizophrenics. Hospital and Community Psychiatry1982;33:983‐4. MandelA , GrossM . Agranulocyctosis and phenothiazines. Diseases of the Nervous System1968;29:32‐6. PrienR , ColeJO . High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health ‐ psychopharmacology research branch collaborative study group. Archives of General Psychiatry1968;18:482‐95. PrienR , DeLongS , ColeJ , LevineJ . Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study. Archives of General Psychiatry1970;23:464‐8. PrienRF , ColeJO , BelkinNF . Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. British Journal of Psychiatry1968;115:679‐86. PrienRF , LevineJ , ColeJO . Indications for high dose chlorpromazine therapy in chronic schizophrenia. Diseases of the Nervous System1970;31:739‐45. ">Prien 1968</a>; <a href="./references#CD000284-bbs2-0050" title="SpohnH , LacoursiereR , ThompsonK , CoyneL . Phenothiazine effects on psychological and psychophysiological dysfunction in chronic schizophrenics. Archives of General Psychiatry1977;34(6):633‐44. ">Spohn 1977</a>) eliminates this heterogeneity. We found longer‐term data (six months to two years) favoured the chlorpromazine group (n=512, 3 RCTs, RR 0.65 CI 0.47 to 0.90), but the two long‐term studies lasting two to five years (<a href="./references#CD000284-bbs2-0030" title="GoldbergS , SchoolerN , HogartyG , RoperM . Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy. Archives of General Psychiatry1977;34:171‐84. HogartyG , GoldbergS . Drug and sociotherapy in the aftercare of schizophrenic patients. One‐year relapse rates. Archives of General Psychiatry1973;28:54‐64. HogartyG , GoldbergS , SchoolerN . Drug and sociotherapy in the aftercare of schizophrenic patients. III. Adjustment of non relapsed patients. Archives of General Psychiatry1974;31:609‐18. HogartyG , GoldbergS , SchoolerN , UlrichR . Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two‐year relapse rates. Archives of General Psychiatry1974;31:603‐8. HogartyG , UlrichR . Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients. Archives of General Psychiatry1977;34:297‐301. HogartyGE , MunetzMR . Pharmacogenic depression among outpatient schizophrenic patients ‐ a failure to substantiate. Journal of Clinical Psychopharmacology1984;4:17‐24. ">Hogarty 1973</a>; <a href="./references#CD000284-bbs2-0034" title="NishikawaT , TsudaA , TanakaM , KogaI , UchidaY . Prophylactic effect of neuroleptics in symptom‐free schizophrenics. Psychopharmacology1982;77:301‐4. ">Nishikawa 1982</a>) showed no difference (n=394, 2 RCTs), again with significant heterogeneity (I<sup>2</sup> = 72% and 84%, respectively). In this case, the larger trials (<a href="./references#CD000284-bbs2-0030" title="GoldbergS , SchoolerN , HogartyG , RoperM . Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy. Archives of General Psychiatry1977;34:171‐84. HogartyG , GoldbergS . Drug and sociotherapy in the aftercare of schizophrenic patients. One‐year relapse rates. Archives of General Psychiatry1973;28:54‐64. HogartyG , GoldbergS , SchoolerN . Drug and sociotherapy in the aftercare of schizophrenic patients. III. Adjustment of non relapsed patients. Archives of General Psychiatry1974;31:609‐18. HogartyG , GoldbergS , SchoolerN , UlrichR . Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two‐year relapse rates. Archives of General Psychiatry1974;31:603‐8. HogartyG , UlrichR . Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients. Archives of General Psychiatry1977;34:297‐301. HogartyGE , MunetzMR . Pharmacogenic depression among outpatient schizophrenic patients ‐ a failure to substantiate. Journal of Clinical Psychopharmacology1984;4:17‐24. ">Hogarty 1973</a>; <a href="./references#CD000284-bbs2-0037" title="CraneGE . Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs. Agressologie1968;2:209‐18. DeLongSL . Incidence and significance of chlorpromazine‐induced eye changes. Diseases of the Nervous System1968;29:19‐22. GardosG , ColeJO , LaBrieRA . A 12‐year follow‐up study of chronic schizophrenics. Hospital and Community Psychiatry1982;33:983‐4. MandelA , GrossM . Agranulocyctosis and phenothiazines. Diseases of the Nervous System1968;29:32‐6. PrienR , ColeJO . High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health ‐ psychopharmacology research branch collaborative study group. Archives of General Psychiatry1968;18:482‐95. PrienR , DeLongS , ColeJ , LevineJ . Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study. Archives of General Psychiatry1970;23:464‐8. PrienRF , ColeJO , BelkinNF . Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. British Journal of Psychiatry1968;115:679‐86. PrienRF , LevineJ , ColeJO . Indications for high dose chlorpromazine therapy in chronic schizophrenia. Diseases of the Nervous System1970;31:739‐45. ">Prien 1968</a>) show a better effect for chlorpromazine and it may well be that the smaller trials are the outlying ones. However, <a href="./references#CD000284-bbs2-0037" title="CraneGE . Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs. Agressologie1968;2:209‐18. DeLongSL . Incidence and significance of chlorpromazine‐induced eye changes. Diseases of the Nervous System1968;29:19‐22. GardosG , ColeJO , LaBrieRA . A 12‐year follow‐up study of chronic schizophrenics. Hospital and Community Psychiatry1982;33:983‐4. MandelA , GrossM . Agranulocyctosis and phenothiazines. Diseases of the Nervous System1968;29:32‐6. PrienR , ColeJO . High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health ‐ psychopharmacology research branch collaborative study group. Archives of General Psychiatry1968;18:482‐95. PrienR , DeLongS , ColeJ , LevineJ . Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study. Archives of General Psychiatry1970;23:464‐8. PrienRF , ColeJO , BelkinNF . Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. British Journal of Psychiatry1968;115:679‐86. PrienRF , LevineJ , ColeJO . Indications for high dose chlorpromazine therapy in chronic schizophrenia. Diseases of the Nervous System1970;31:739‐45. ">Prien 1968</a> includes a high‐dose treatment arm (2000 mg/day of chlorpromazine), which may explain some of the heterogeneity in the results, see the subgroup analysis (<a href="./references#CD000284-fig-0026" title="">Analysis 1.23</a>) below. </p> </section> <section id="CD000284-sec-0130"> <h5 class="title">1.3 Global state</h5> <section id="CD000284-sec-0131"> <h6 class="title">1.3.1 No overall improvement</h6> <p>We found short‐term global state data ('no overall improvement' ‐ psychiatrist‐rated ; <a href="./references#CD000284-fig-0006" title="">Analysis 1.3</a>) significantly favoured chlorpromazine (n=728, 13 RCTs, RR 0.61 CI 0.46 to 0.82) compared with placebo. Medium‐term data up to six months also favoured chlorpromazine (n=1164, 14 RCTs, RR 0.71 CI 0.58 to 0.86). There was significant heterogeneity at both short term and medium term (I<sup>2</sup>=69% and 81%, respectively). There were no obviously outlying trials for this outcome at short term, so none were removed from the analysis. For medium term, removal of the largest trial, <a href="./references#CD000284-bbs2-0037" title="CraneGE . Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs. Agressologie1968;2:209‐18. DeLongSL . Incidence and significance of chlorpromazine‐induced eye changes. Diseases of the Nervous System1968;29:19‐22. GardosG , ColeJO , LaBrieRA . A 12‐year follow‐up study of chronic schizophrenics. Hospital and Community Psychiatry1982;33:983‐4. MandelA , GrossM . Agranulocyctosis and phenothiazines. Diseases of the Nervous System1968;29:32‐6. PrienR , ColeJO . High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health ‐ psychopharmacology research branch collaborative study group. Archives of General Psychiatry1968;18:482‐95. PrienR , DeLongS , ColeJ , LevineJ . Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study. Archives of General Psychiatry1970;23:464‐8. PrienRF , ColeJO , BelkinNF . Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. British Journal of Psychiatry1968;115:679‐86. PrienRF , LevineJ , ColeJO . Indications for high dose chlorpromazine therapy in chronic schizophrenia. Diseases of the Nervous System1970;31:739‐45. ">Prien 1968</a>, restores homogeneity, an effect that does not appear in the subgroup analysis for high versus low dose, see the subgroup analysis (<a href="./references#CD000284-fig-0026" title="">Analysis 1.23</a>) below, and again, it may be the smaller trials that are outliers. </p> <p>Nurse‐rated global state 'no overall improvement' scores (<a href="./references#CD000284-fig-0007" title="">Analysis 1.4</a>) were equivocal at short‐term assessment in one small study (<a href="./references#CD000284-bbs2-0054" title="WeckowiczTE , WardT . Clinical trial of RO 5‐0690 and chlorpromazine on disturbed chronic schizophrenic patients. Diseases of the Nervous System1960;21:527‐8. [MEDLINE: 13783681] ">Weckowicz 1960</a>) (n=29, RR 0.91 CI 0.65 to 1.27). However, scores from one research group (<a href="./references#CD000284-bbs2-0011" title="ClarkM , DubowskiK , ColmoreJ . The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clinical Pharmacology and Therapeutics1970;11:883‐9. ClarkML , HuberWK , SakataK , FowlesDC , SerafetinidesEA . Molindone in chronic schizophrenia. Clinical Pharmacology and Therapeutics1970;11:680‐8. SerafetinidesEA , WillisD , ClarkML . The EEG effects of chemically and clinically dissimilar antipsychotics: molindone vs. chlorpromazine. International Pharmacopsychiatry1971;6:77‐82. ">Clark 1970a</a>; <a href="./references#CD000284-bbs2-0014" title="ClarkML , HuberWK , SullivanJ , WoodF , CostiloeJP . Evaluation of loxapine succinate in chronic schizophrenia. Diseases of the Nervous System1972;33:783‐91. SerafetinidesEA , WillisD , ClarkML . The EEG effects of dibenzoxazepines (loxapine succinate) as compared to CPZ: EEG changes as drug side effects. International Pharmacopsychiatry1971;6:38‐44. ">Clark 1972</a>; <a href="./references#CD000284-bbs2-0015" title="ClarkML , ParedesA , CostiloeJP , WoodF . Evaluation of butaclamol in chronic schizophrenic patients. Journal of Clinical Pharmacology1977;17:529‐36. ">Clark 1977</a>) favoured chlorpromazine at medium‐term assessment (n=84, 3 RCTs, RR 0.48 CI 0.35 to 0.64). Similar data were recorded in continuous form in only one small study (<a href="./references#CD000284-bbs2-0005" title="BorisonRL , DiamondBI , DrenAT . Does sigma receptor antagonism predict clinical antipsychotic efficacy?. Psychopharmacology Bulletin1991;27:103‐6. BorisonRL , DrenAT , DiamondBI . Sigma receptor antagonism and antipsychotic actions in schizophrenic patients. European Journal of Pharmacology1990;183:23. ">Borison 1991</a>) and results were equivocal (n=19, 1 RCT; <a href="./references#CD000284-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD000284-sec-0132"> <h6 class="title">1.3.2 Severity of illness</h6> <p>We found estimates by psychiatrists for the severity of illness (<a href="./references#CD000284-fig-0009" title="">Analysis 1.6</a>) were equivocal at short‐term assessments (n=44, 1 RCT) however, medium‐term data showed significantly greater improvement in the chlorpromazine group (n=694, 3 RCTs, RR 0.80 CI 0.74 to 0.86) compared with placebo. Nurse‐rated severity of illness scores (<a href="./references#CD000284-fig-0010" title="">Analysis 1.7</a>) also favoured the chlorpromazine group (medium term, n=66, 2 RCTs, RR 0.63 CI 0.45 to 0.90) compared with placebo. </p> </section> </section> <section id="CD000284-sec-0133"> <h5 class="title">1.4 Leaving the study early</h5> <p>People allocated to chlorpromazine are more likely to remain in the study than participants given placebo (<a href="./references#CD000284-fig-0011" title="">Analysis 1.8</a>), in both short‐ (n=1065, 17 RCTs, RR 0.76 CI 0.63 to 0.92) and medium‐term studies (n=1831, 27 RCTs, RR 0.64 CI 0.53 to 0.78). The short‐term studies showed some heterogeneity (I<sup>2</sup> = 51%). When we analyse the data using random‐effects, the result becomes non‐significant (n=1065, 17 RCTs, RR 0.80 CI0.58 to 1.10). Removing the study with results that were causing this heterogeneity, as judged by visual inspection (<a href="./references#CD000284-bbs2-0017" title="ColeJO , GoldbergSC , Klerman GL National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group. Phenothiazine treatment in acute schizophrenia. Archives of General Psychiatry1964;10:246‐61. GoldbergS , KlermanG , ColeJ . Changes in schizophrenic psychopathology and ward behaviour as a function of phenothiazine treatment. British Journal of Psychiatry1965;111:120‐33. GoldbergSC , MattssonNB . Schizophrenic subtypes defined by response to drugs and placebo. Diseases of the Nervous System1968;29:153‐8. ">Cole 1964</a>, which used very high doses of chlorpromazine in one arm of the trial) eliminates this heterogeneity. However, we did not find any significant differences in attrition rates from the comparatively large studies (<a href="./references#CD000284-bbs2-0020" title="EngelhardtD , FreedmanN , RosenB , MannD , MargolisR . Phenothiazines in prevention of psychiatric hospitalization. Archives of General Psychiatry1964;11:162‐9. EngelhardtDM , FreedmanN , GlickBS , HankoffLD , MannD , MargolisR . Prevention of psychiatric hospitalization with use of psychopharmacological agents. JAMA1960;173:147‐9. EngelhardtDM , MargolisRA , RudorferL , PaleyHM . Physician bias and the double‐blind. Archives of General Psychiatry1969;20(3):315‐20. EngelhardtDM , RosenB , FreedmanN , MannD , MargolisR . Phenothiazines in prevention of psychiatric hospitalization. II. Duration of treatment exposure. JAMA1963;186:981‐3. EngelhardtDM , RosenB , FreedmanN , MargolisR . Phenothiazines in prevention of psychiatric hospitalization. IV. Delay or prevention of hospitalization ‐ a reevaluation. Archives of General Psychiatry1967;16:98‐101. FreedmanN , CutlerR , EngelhardtDM , MargolisR . On the modification of paranoid symptomatology. Journal of Nervous and Mental Disease1967;144:29‐36. FreedmanN , CutlerR , EngelhardtDM , MargolisR . On the modification of paranoid symptomatology. II. Stylistic considerations and the effectiveness of phenothiazines. Journal of Nervous and Mental Disease1970;150:68‐76. RosenB , EngelhardtDM , FreedmanN . The hospitalization proneness scale as a predictor of response to phenothiazine treatment. Journal of Nervous and Mental Disease1968;6:476‐80. ">Engelhardt 1960</a>, <a href="./references#CD000284-bbs2-0030" title="GoldbergS , SchoolerN , HogartyG , RoperM . Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy. Archives of General Psychiatry1977;34:171‐84. HogartyG , GoldbergS . Drug and sociotherapy in the aftercare of schizophrenic patients. One‐year relapse rates. Archives of General Psychiatry1973;28:54‐64. HogartyG , GoldbergS , SchoolerN . Drug and sociotherapy in the aftercare of schizophrenic patients. III. Adjustment of non relapsed patients. Archives of General Psychiatry1974;31:609‐18. HogartyG , GoldbergS , SchoolerN , UlrichR . Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two‐year relapse rates. Archives of General Psychiatry1974;31:603‐8. HogartyG , UlrichR . Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients. Archives of General Psychiatry1977;34:297‐301. HogartyGE , MunetzMR . Pharmacogenic depression among outpatient schizophrenic patients ‐ a failure to substantiate. Journal of Clinical Psychopharmacology1984;4:17‐24. ">Hogarty 1973</a>, n=492), which were conducted for up to two years. Also, longer‐term data (<a href="./references#CD000284-bbs2-0030" title="GoldbergS , SchoolerN , HogartyG , RoperM . Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy. Archives of General Psychiatry1977;34:171‐84. HogartyG , GoldbergS . Drug and sociotherapy in the aftercare of schizophrenic patients. One‐year relapse rates. Archives of General Psychiatry1973;28:54‐64. HogartyG , GoldbergS , SchoolerN . Drug and sociotherapy in the aftercare of schizophrenic patients. III. Adjustment of non relapsed patients. Archives of General Psychiatry1974;31:609‐18. HogartyG , GoldbergS , SchoolerN , UlrichR . Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two‐year relapse rates. Archives of General Psychiatry1974;31:603‐8. HogartyG , UlrichR . Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients. Archives of General Psychiatry1977;34:297‐301. HogartyGE , MunetzMR . Pharmacogenic depression among outpatient schizophrenic patients ‐ a failure to substantiate. Journal of Clinical Psychopharmacology1984;4:17‐24. ">Hogarty 1973</a>) did not demonstrate a significant difference in retention rates. </p> </section> <section id="CD000284-sec-0134"> <h5 class="title">1.5 Mental state</h5> <p>There are only a few studies with usable data relating to mental state.</p> <section id="CD000284-sec-0135"> <h6 class="title">1.5.1 Improved (50% reduction in BPRS)</h6> <p>We found no short‐term difference in mental state using a cut‐off point of at least a 50% decline in score to indicate 'improvement' (<a href="./references#CD000284-bbs2-0018" title="CooperSJ , ButlerA , TweedJ , WelchCP . Zotepine in the treatment of chronic schizophrenia. 10th ECNP (European College of Neuropsychopharmacology) Congress. Vienna, Austria. Vienna, Austria, September 13‐17, 1997. CooperSJ , RaniwallaJ , WelchC . Zotepine in acute exacerbation of schizophrenia: a comparison versus chlorpromazine and placebo. XXth Collegium Internationale Neuro‐psychopharmacologicum. Melbourne, Australia. Melbourne, Australia, 1996. CooperSJ , TweedJ , RaniwallaJ , ButlerA , WelchC . A placebo controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatrica Scandinavica2000;101(3):218‐25. [MEDLINE: 20184895] CooperSJ , TweedJ , RaniwallaJ , WelchC . A placebo‐controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Unpublished manuscript1996. CooperSJ , WelchCP . A comparison of zotepine and chlorpromazine on BPRS subscores. 10th ECNP (European College of Neuropsychopharmacology) Congress. Vienna, Austria. Vienna, Austria, September 13‐17, 1997. ">Cooper 2000</a>, n=106; <a href="./references#CD000284-fig-0012" title="">Analysis 1.9</a>). </p> </section> <section id="CD000284-sec-0136"> <h6 class="title">1.5.2 Average endpoint score (BPRS)</h6> <p>What continuous data there are favour chlorpromazine at short‐ (n=49, 2 RCTs, MD ‐4.82 CI ‐8.48 to ‐1.15) and medium‐term assessments (<a href="./references#CD000284-bbs2-0051" title="TetreaultL . Comparative study of two drugs and a placebo in chronic schizophrenia [Etude comparative de deux medicaments et d'un placebo chez le schizophrene chronique]. Actualites Pharmacologiques1969;22:221‐8. TetreaultL , BordeleauJM , GauthierR , VulpeM , LapointeL . Comparative study of TPS‐23, chlorpromazine and placebo in chronic schizophrenic patients. Diseases of the Nervous System1969;30(2):74‐84. ">Tetreault 1969</a>, n=30, MD ‐7.70 CI ‐14.77 to ‐0.63) (<a href="./references#CD000284-fig-0013" title="">Analysis 1.10</a>). </p> </section> <section id="CD000284-sec-0137"> <h6 class="title">1.5.3 Average change score (BPRS)</h6> <p>See <a href="#CD000284-tbl-0002">Table 1</a>. </p> <div class="table" id="CD000284-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Mental state: 3. Average BPRS change score (large decline=best)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Chlorpromazine mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Chlorpromazine SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Chlorpromazine N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo N</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000284-bbs2-0018" title="CooperSJ , ButlerA , TweedJ , WelchCP . Zotepine in the treatment of chronic schizophrenia. 10th ECNP (European College of Neuropsychopharmacology) Congress. Vienna, Austria. Vienna, Austria, September 13‐17, 1997. CooperSJ , RaniwallaJ , WelchC . Zotepine in acute exacerbation of schizophrenia: a comparison versus chlorpromazine and placebo. XXth Collegium Internationale Neuro‐psychopharmacologicum. Melbourne, Australia. Melbourne, Australia, 1996. CooperSJ , TweedJ , RaniwallaJ , ButlerA , WelchC . A placebo controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatrica Scandinavica2000;101(3):218‐25. [MEDLINE: 20184895] CooperSJ , TweedJ , RaniwallaJ , WelchC . A placebo‐controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Unpublished manuscript1996. CooperSJ , WelchCP . A comparison of zotepine and chlorpromazine on BPRS subscores. 10th ECNP (European College of Neuropsychopharmacology) Congress. Vienna, Austria. Vienna, Austria, September 13‐17, 1997. ">Cooper 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53 (LOCF)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53 (LOCF)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>LOCF ‐ last observation carried forward</p> </div> </div> </section> </section> <section id="CD000284-sec-0138"> <h5 class="title">1.6 Behaviour</h5> <section id="CD000284-sec-0139"> <h6 class="title">1.6.1 Deteriorated/disturbed/un‐cooperative</h6> <p>We found participants did not differ significantly in experiencing a worsening in their behaviour (<a href="./references#CD000284-fig-0014" title="">Analysis 1.11</a>) at short‐term assessment (n=87, 2 RCTs), although data are heterogeneous (I<sup>2</sup>=65%). Medium‐term data also did not differ significantly (n=1040, 8 RCTs), but again, data are heterogeneous (I<sup>2</sup>=90%). There are no obviously outlying studies as all confidence intervals overlap. Removing the possibly outlying studies, either <a href="./references#CD000284-bbs2-0037" title="CraneGE . Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs. Agressologie1968;2:209‐18. DeLongSL . Incidence and significance of chlorpromazine‐induced eye changes. Diseases of the Nervous System1968;29:19‐22. GardosG , ColeJO , LaBrieRA . A 12‐year follow‐up study of chronic schizophrenics. Hospital and Community Psychiatry1982;33:983‐4. MandelA , GrossM . Agranulocyctosis and phenothiazines. Diseases of the Nervous System1968;29:32‐6. PrienR , ColeJO . High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health ‐ psychopharmacology research branch collaborative study group. Archives of General Psychiatry1968;18:482‐95. PrienR , DeLongS , ColeJ , LevineJ . Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study. Archives of General Psychiatry1970;23:464‐8. PrienRF , ColeJO , BelkinNF . Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. British Journal of Psychiatry1968;115:679‐86. PrienRF , LevineJ , ColeJO . Indications for high dose chlorpromazine therapy in chronic schizophrenia. Diseases of the Nervous System1970;31:739‐45. ">Prien 1968</a> or <a href="./references#CD000284-bbs2-0025" title="HallRA , DunlapDJ . A study of chlorpromazine: methodology and results with chronic semi‐disturbed schizophrenics. Journal of Nervous and Mental Disease1955;122:301‐14. HollisterLE , HallRA . Phenothiazine derivatives and morphologic changes in the liver. American Journal of Psychiatry1966;123:211‐2. ">Hall 1955</a>, does not restore homogeneity, nor does their removal change the results. </p> </section> <section id="CD000284-sec-0140"> <h6 class="title">1.6.2 Unchanged</h6> <p>Both short‐term (<a href="./references#CD000284-bbs2-0044" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic, hospitalized, schizophrenic patients. Journal of Clinical and Experiemental Psychopathology1961;22:151‐62. ">Schiele 1961</a>, n=40) and medium‐term (n=68, 2 RCTs) dichotomous data did not reveal any significant differences between chlorpromazine and placebo when assessing change in participants behaviour (<a href="./references#CD000284-fig-0015" title="">Analysis 1.12</a>). </p> </section> <section id="CD000284-sec-0141"> <h6 class="title">1.6.3 Rosenthal Rating Scale</h6> <p><a href="./references#CD000284-bbs2-0051" title="TetreaultL . Comparative study of two drugs and a placebo in chronic schizophrenia [Etude comparative de deux medicaments et d'un placebo chez le schizophrene chronique]. Actualites Pharmacologiques1969;22:221‐8. TetreaultL , BordeleauJM , GauthierR , VulpeM , LapointeL . Comparative study of TPS‐23, chlorpromazine and placebo in chronic schizophrenic patients. Diseases of the Nervous System1969;30(2):74‐84. ">Tetreault 1969</a> provided data from the Rosenthal Rating Scale (<a href="./references#CD000284-fig-0016" title="">Analysis 1.13</a>) and we found short‐term data were not significantly different (n=30, 1 RCT) between chlorpromazine and the placebo group. Medium‐term data were also not significantly different (n=30, 1 RCT). </p> </section> <section id="CD000284-sec-0142"> <h6 class="title">1.6.4 Parkside Behaviour Rating Scale</h6> <p><a href="./references#CD000284-bbs2-0002" title="BakerJP . A controlled trial of ethylcrotonylurea. British Journal of Psychiatry1959;105:852‐62. ">Baker 1959</a> used the Parkside Behaviour Rating Scale (<a href="./references#CD000284-fig-0017" title="">Analysis 1.14</a>) to assess behaviour and we found that those given chlorpromazine had a significantly better rating in their behaviour compared with the placebo group (n=14, MD 6.00 CI 1.97 to 10.03). </p> </section> <section id="CD000284-sec-0143"> <h6 class="title">1.6.5 Fergus Falls Behavioural Rating Scale</h6> <p><a href="./references#CD000284-bbs2-0039" title="RamuMG , ChaturvediDD , VenkataramBS , ShankaraMR , LeelavathyS , JanakiramiahN , et al. A DOUBLE BLIND controlled study on the role of brahmyadiyoga and tagara in jirnomada (chronic schizophrenia). Ayurvedic Management of Unmada (Schizophrenia). New Delhi: Central Council for Research in Ayurveda &amp; Siddha, 1999:77‐88. ">Ramu 1999a</a> used the Fergus Falls Behavioural Rating Scale (<a href="./references#CD000284-fig-0018" title="">Analysis 1.15</a>) to assess change in behaviour of participants and we found that behaviour was not significantly different (n=42, 1 RCT) between chlorpromazine and the placebo group. </p> </section> </section> <section id="CD000284-sec-0144"> <h5 class="title">1.7 Adverse effects</h5> <section id="CD000284-sec-0145"> <h6 class="title">1.7.1 Extrapyramidal symptoms</h6> <p>There is evidence that chlorpromazine increases a person's chances of experiencing acute movement disorders (dystonia) (n=942, 5 RCTs, RR 3.47 CI 1.50 to 8.03), parkinsonism (n=1468, 15 RCTs, RR 2.11 CI 1.59 to 2.80), tremor (n=392, 7 RCTs, RR 1.66 CI 1.01 to 2.73) and rigidity (n=412, 7 RCTs, RR 2.24 CI 1.42 to 3.54). Akathisia (subjective feeling of restlessness that may lead to agitation) was dominated by one trial (<a href="./references#CD000284-bbs2-0037" title="CraneGE . Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs. Agressologie1968;2:209‐18. DeLongSL . Incidence and significance of chlorpromazine‐induced eye changes. Diseases of the Nervous System1968;29:19‐22. GardosG , ColeJO , LaBrieRA . A 12‐year follow‐up study of chronic schizophrenics. Hospital and Community Psychiatry1982;33:983‐4. MandelA , GrossM . Agranulocyctosis and phenothiazines. Diseases of the Nervous System1968;29:32‐6. PrienR , ColeJO . High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health ‐ psychopharmacology research branch collaborative study group. Archives of General Psychiatry1968;18:482‐95. PrienR , DeLongS , ColeJ , LevineJ . Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study. Archives of General Psychiatry1970;23:464‐8. PrienRF , ColeJO , BelkinNF . Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. British Journal of Psychiatry1968;115:679‐86. PrienRF , LevineJ , ColeJO . Indications for high dose chlorpromazine therapy in chronic schizophrenia. Diseases of the Nervous System1970;31:739‐45. ">Prien 1968</a>) and did not occur more frequently in the chlorpromazine group than placebo (n=1164, 9 RCTs), nor did tardive dyskinesia (<a href="./references#CD000284-bbs2-0015" title="ClarkML , ParedesA , CostiloeJP , WoodF . Evaluation of butaclamol in chronic schizophrenic patients. Journal of Clinical Pharmacology1977;17:529‐36. ">Clark 1977</a>, n=18) nor ataxia (<a href="./references#CD000284-bbs2-0028" title="HankoffLD , RudorferL , PaleyHM . A reference study of ataraxics. A two‐week double blind outpatient evaluation. Journal of New Drugs1962;2:173‐8. [MEDLINE: 13904352] ">Hankoff 1962</a>, n=97). We found extrapyramidal adverse effects were equivocal at both short‐ and medium‐term assessments from one small scale study (n=30) by <a href="./references#CD000284-bbs2-0051" title="TetreaultL . Comparative study of two drugs and a placebo in chronic schizophrenia [Etude comparative de deux medicaments et d'un placebo chez le schizophrene chronique]. Actualites Pharmacologiques1969;22:221‐8. TetreaultL , BordeleauJM , GauthierR , VulpeM , LapointeL . Comparative study of TPS‐23, chlorpromazine and placebo in chronic schizophrenic patients. Diseases of the Nervous System1969;30(2):74‐84. ">Tetreault 1969</a>. (See <a href="./references#CD000284-fig-0019" title="">Analysis 1.16</a>; <a href="./references#CD000284-fig-0020" title="">Analysis 1.17</a>). </p> </section> <section id="CD000284-sec-0146"> <h6 class="title">1.7.2 Central nervous system</h6> <p>Chlorpromazine is clearly sedating (n=1627, 23 RCTs, RR 2.79 CI 2.25 to 3.45). There is also evidence that chlorpromazine increases a person's chances of experiencing fits (n=695, 3 RCTs, RR 3.11 CI 1.05 to 9.18) and weakness (n=92, 3 RCTs, RR 3.33 CI 1.02 to 10.88). Convulsions did not occur more frequently in the chlorpromazine group than placebo (<a href="./references#CD000284-bbs2-0024" title="GwynneP , HundziakM , KavtschitschJ , LeftonM , PasamanickB . Efficacy of trifluoperazine on withdrawal in chronic schizophrenia. Journal of Nervous and Mental Disease1962;134:451‐5. [MEDLINE: 13903283] ">Gwynne 1962</a>, n=52; <a href="./references#CD000284-fig-0021" title="">Analysis 1.18</a>). </p> </section> <section id="CD000284-sec-0147"> <h6 class="title">1.7.3 Blood, skin, liver and eyes</h6> <p>We found no significant differences in blood problems such as agranulocytosis and leucopenia (n=394, 7 RCTs), or rashes and itching (n=1313, 13 RCTs). Liver problems, mainly jaundice were also not significant (n=249, 4 RCTs). Further data from early trials suggest that chlorpromazine may well cause photosensitivity (n=799, 6 RCTs, RR 6.04 CI 3.22 to 11.32), and eye opacities or pigment problems (n=657, 2 RCTs, RR 3.09 CI 1.87 to 5.11) when large dosages of chlorpromazine are used. (See <a href="./references#CD000284-fig-0022" title="">Analysis 1.19</a>). </p> </section> <section id="CD000284-sec-0148"> <h6 class="title">1.7.4 Other</h6> <p>Chlorpromazine clearly causes a lowering of blood pressure with accompanying dizziness (n=1488, 18 RCTs, RR 2.38 CI 1.74 to 3.25). Chlorpromazine is constipating, when compared with placebo (n=1117, 10 RCTs, RR 2.05 CI 1.33 to 3.15). We found data that urinary problems (n=926, 5 RCTs), and also blurred vision were not significantly different between chlorpromazine and placebo. We found that chlorpromazine does cause dry mouth (n=1015, 7 RCTs, RR 4.56 CI 2.35 to 8.85). Chlorpromazine increases participants’ weight (n=165, 5 RCTs, RR 4.92 CI 2.32 to 10.43). We found significantly more participants given chlorpromazine experienced nausea (n=1024, 5 RCTs, RR 2.07 CI 1.14 to 3.73). Salivation occurred significantly more frequently in the chlorpromazine group (n=830, 3TCTs, RR 3.37 CI 1.07 to 10.57). We found no clear evidence that chlorpromazine precipitates the frequency of amenorrhoea, menorrhagia or lactation problems. (See <a href="./references#CD000284-fig-0023" title="">Analysis 1.20</a>). </p> </section> </section> </section> <section id="CD000284-sec-0149"> <h4 class="title">2. Subgroup analyses</h4> <section id="CD000284-sec-0150"> <h5 class="title">2.1 Men versus women</h5> <p>Few studies reported outcomes for only men or women. The only primary outcome for which data were available for comparison is 'Behaviour deteriorated/disturbed/uncooperative' (<a href="./references#CD000284-fig-0024" title="">Analysis 1.21</a>). <a href="./references#CD000284-bbs2-0044" title="SchieleBC , VestreND , SteinKE . A comparison of thioridazine, chlorpromazine, and placebo: a double‐blind controlled study on the treatment of chronic, hospitalized, schizophrenic patients. Journal of Clinical and Experiemental Psychopathology1961;22:151‐62. ">Schiele 1961</a> included only men (n=40) and three studies report the same outcome for women alone (<a href="./references#CD000284-bbs2-0012" title="ClarkM , DubowskiK , ColmoreJ . The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clinical Pharmacology and Therapeutics1970;11:883‐9. ClarkM , RamseyH , RahhalD , SerafetinidesE , WoodF , CostiloeJ . Chlorpromazine in chronic schizophrenia. The effect of age and hospitalization on behavioral dose‐response relationships. Archives of General Psychiatry1972;27:479‐83. ClarkML , RamseyHR , RaglandRE , RahhalDK , SerafetinidesEA , CostiloeJP . Chlorpromazine in chronic schizophrenia ‐ behavioral dose‐response relationships. Psychopharmacologia1970;18:260‐70. SerafetinidesEA , WillisD , ClarkML . EEG dose‐response relationships of chlorpromazine in chronic schizophrenia: the effects on the various rhythms and on alpha blocking. Biological Psychiatry1972;4:251‐6. ">Clark 1970b</a>; <a href="./references#CD000284-bbs2-0022" title="FlemingB , SpencerA , WhitelawE . A controlled comparative investigation of the effects of promazine, chlorpromazine, and a placebo in chronic psychosis. British Journal of Psychiatry1959;105:349‐58. ">Fleming 1959</a>; <a href="./references#CD000284-bbs2-0049" title="SomervilleDM , CohenPH , GravesGD . Phenothiazine side‐effects. Comparison of two major tranquillizers. British Journal of Psychiatry1960;106:1417‐24. ">Somerville 1960</a>, total n=158). Results of randomised trials were equally significant for the subgroups. </p> </section> <section id="CD000284-sec-0151"> <h5 class="title">2.2 Under 18 years of age versus 18‐65 years old versus older than 65</h5> <p>We could not perform this subgroup analysis as data were only available for people between the ages of 18 and 64 years. </p> </section> <section id="CD000284-sec-0152"> <h5 class="title">2.3 Acutely ill people (&lt; one month in duration) versus people who have been ill for longer </h5> <p>Limited data were available for a few primary outcomes (<a href="./references#CD000284-fig-0025" title="">Analysis 1.22</a>). We found that people who were chronically ill were more likely to have improved for short‐ and medium‐term global improvement, and disturbed behaviour compared with those whose illnesses were acute. No difference was found for rates of relapse between acute and chronic participants. Results of randomised trials were equally significant for all subgroups. However, these analyses are severely limited by the lack of studies in the acutely ill groups and no firm conclusion can be made. </p> </section> <section id="CD000284-sec-0153"> <h5 class="title">2.4 High dose (&gt; 501 mg/day) versus low doses (1‐500 mg/day)</h5> <p>For the outcome of relapse between nine weeks and six months, the high‐dose arm of <a href="./references#CD000284-bbs2-0037" title="CraneGE . Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs. Agressologie1968;2:209‐18. DeLongSL . Incidence and significance of chlorpromazine‐induced eye changes. Diseases of the Nervous System1968;29:19‐22. GardosG , ColeJO , LaBrieRA . A 12‐year follow‐up study of chronic schizophrenics. Hospital and Community Psychiatry1982;33:983‐4. MandelA , GrossM . Agranulocyctosis and phenothiazines. Diseases of the Nervous System1968;29:32‐6. PrienR , ColeJO . High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health ‐ psychopharmacology research branch collaborative study group. Archives of General Psychiatry1968;18:482‐95. PrienR , DeLongS , ColeJ , LevineJ . Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study. Archives of General Psychiatry1970;23:464‐8. PrienRF , ColeJO , BelkinNF . Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. British Journal of Psychiatry1968;115:679‐86. PrienRF , LevineJ , ColeJO . Indications for high dose chlorpromazine therapy in chronic schizophrenia. Diseases of the Nervous System1970;31:739‐45. ">Prien 1968</a> reports statistically significantly more favourable results for the chlorpromazine group, compared with the low‐dose group of studies (P &lt; 0.005). However, for the low‐dose subgroup there remains significant heterogeneity that is not explained by the exclusion of the high‐dose arm of <a href="./references#CD000284-bbs2-0037" title="CraneGE . Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs. Agressologie1968;2:209‐18. DeLongSL . Incidence and significance of chlorpromazine‐induced eye changes. Diseases of the Nervous System1968;29:19‐22. GardosG , ColeJO , LaBrieRA . A 12‐year follow‐up study of chronic schizophrenics. Hospital and Community Psychiatry1982;33:983‐4. MandelA , GrossM . Agranulocyctosis and phenothiazines. Diseases of the Nervous System1968;29:32‐6. PrienR , ColeJO . High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health ‐ psychopharmacology research branch collaborative study group. Archives of General Psychiatry1968;18:482‐95. PrienR , DeLongS , ColeJ , LevineJ . Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study. Archives of General Psychiatry1970;23:464‐8. PrienRF , ColeJO , BelkinNF . Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. British Journal of Psychiatry1968;115:679‐86. PrienRF , LevineJ , ColeJO . Indications for high dose chlorpromazine therapy in chronic schizophrenia. Diseases of the Nervous System1970;31:739‐45. ">Prien 1968</a>. For the short‐ and medium‐term outcome 'no global improvement', there is no clear difference between studies using high‐dose chlorpromazine to low dose. Higher dosages of chlorpromazine did not confer an advantage in reducing behavioural disturbances, compared with the low‐dose group (<a href="./references#CD000284-fig-0026" title="">Analysis 1.23</a>). </p> </section> <section id="CD000284-sec-0154"> <h5 class="title">2.5 People diagnosed according to any operational criteria versus those who have not been diagnosed using operational criteria </h5> <p>For relapse in short‐term studies, the any operational criteria group had a better outcome but the sample size is too small to enable conclusions to be made. Relapse in medium‐term studies favoured participants diagnosed with operational criteria (P &lt; 0.04). Global impression 'not improved' revealed no differences in the short and medium term. There were no apparent differences for severity of illness and behaviour (<a href="./references#CD000284-fig-0027" title="">Analysis 1.24</a>). </p> </section> <section id="CD000284-sec-0155"> <h5 class="title">2.6 Studies published before 1990 versus studies published between 1990 and the present</h5> <p>Data were available for the outcomes of 'no overall improvement' in the short term and medium term, and 'behaviour deteriorated/disturbed/uncooperative' (<a href="./references#CD000284-fig-0028" title="">Analysis 1.25</a>). Few studies were available in the 1990 to 2007 group limiting the analysis. Results of randomised trials were equally significant for all subgroups. </p> </section> </section> <section id="CD000284-sec-0156"> <h4 class="title">3. Sensitivity analyses</h4> <section id="CD000284-sec-0157"> <h5 class="title">3.1 Implication of randomisation</h5> <p>For the outcome ‘no overall improvement’ in the medium term, there were no differences in the results for one study (<a href="./references#CD000284-bbs2-0039" title="RamuMG , ChaturvediDD , VenkataramBS , ShankaraMR , LeelavathyS , JanakiramiahN , et al. A DOUBLE BLIND controlled study on the role of brahmyadiyoga and tagara in jirnomada (chronic schizophrenia). Ayurvedic Management of Unmada (Schizophrenia). New Delhi: Central Council for Research in Ayurveda &amp; Siddha, 1999:77‐88. ">Ramu 1999a</a>) that only implied randomisation and studies that explicitly stated that they were randomised (<a href="./references#CD000284-fig-0029" title="">Analysis 1.26</a>). </p> </section> <section id="CD000284-sec-0158"> <h5 class="title">3.2 Assumptions for lost binary data</h5> <p>Two studies made assumptions regarding people lost to follow‐up for the outcome ‘no overall improvement’ in the short term; no differences were found (<a href="./references#CD000284-fig-0030" title="">Analysis 1.27</a>). </p> </section> <section id="CD000284-sec-0159"> <h5 class="title">3.3 Risk of bias</h5> <p>None of the studies had a high risk of bias for allocation concealment, or blinding of participants and outcome assessors (see <a href="#CD000284-fig-0002">Figure 2</a>). Those that had a high risk of bias for randomisation were included in the sensitivity analysis above (<a href="./references#CD000284-fig-0029" title="">Analysis 1.26</a>). </p> </section> <section id="CD000284-sec-0160"> <h5 class="title">3.4 Imputed values</h5> <p>We did not undertake a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC as there were no cluster‐randomised trials included in the review. </p> </section> <section id="CD000284-sec-0161"> <h5 class="title">3.5 Dishonest researchers</h5> <p>It has come to our attention that Dr Richard Borison and Dr Bruce Diamond have been convicted of theft, making false statements and violations of state racketeering law in the USA. At this point, it seems that the crimes were to do with criminal diversion of funds, rather than falsifying study data (http://www.the‐scientist.com/yr1998/oct/notebook_981026.html). Nevertheless, we temporarily removed studies with either of these authors from the analyses to see if this made a substantive difference to the findings. <a href="./references#CD000284-bbs2-0005" title="BorisonRL , DiamondBI , DrenAT . Does sigma receptor antagonism predict clinical antipsychotic efficacy?. Psychopharmacology Bulletin1991;27:103‐6. BorisonRL , DrenAT , DiamondBI . Sigma receptor antagonism and antipsychotic actions in schizophrenic patients. European Journal of Pharmacology1990;183:23. ">Borison 1991</a> presented usable data on mental state (average endpoint score on BPRS), the removal of this study did not result in a substantive change in the findings. <a href="./references#CD000284-bbs2-0005" title="BorisonRL , DiamondBI , DrenAT . Does sigma receptor antagonism predict clinical antipsychotic efficacy?. Psychopharmacology Bulletin1991;27:103‐6. BorisonRL , DrenAT , DiamondBI . Sigma receptor antagonism and antipsychotic actions in schizophrenic patients. European Journal of Pharmacology1990;183:23. ">Borison 1991</a> is the reports one unique outcome for global state (average endpoint score on Clinical Global Impression (CGI)), so removal of the study results in the deletion of the complete outcome. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD000284-sec-0162" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD000284-sec-0162"></div> <section id="CD000284-sec-0163"> <h3 class="title" id="CD000284-sec-0163">Summary of main results</h3> <p>The summary below reflects the outcomes chosen for the <a href="./full#CD000284-tbl-0001">summary of findings Table for the main comparison</a>, and considered the main findings of this review that can support evidence‐based decision making. </p> <section id="CD000284-sec-0164"> <h4 class="title">1. Death</h4> <p>It may be surprising that there were no more deaths reported among over 5000 people with schizophrenia who were randomised to chlorpromazine or placebo. The lifetime incidence of suicide for people suffering from schizophrenia is 10% to 13% (<a href="./references#CD000284-bbs2-0380" title="CaldwellCB , GottesmanII . Schizophrenia ‐ a high‐risk factor for suicide: clues to risk reduction. Suicide and Life‐Threatening Behavior1992;22:479‐93. ">Caldwell 1992</a>). Furthermore, the use of large doses of neuroleptic has been associated with sudden death (<a href="./references#CD000284-bbs2-0400" title="JusicN , LaderM . Post‐mortem antipsychotic drug concentrations and unexplained deaths. British Journal of Psychiatry1994;165:787‐91. ">Jusic 1994</a>), but there are no records of such events within this review. The fact that there are none may reflect the fact that either trial‐care is more vigilant than routine care or that death is an under‐reported outcome. </p> </section> <section id="CD000284-sec-0165"> <h4 class="title">2. Relapse</h4> <p>Chlorpromazine reduced the number of participants experiencing a relapse compared with placebo during six months to two years follow‐up, but not in the short, medium or long term over two years, although data were heterogeneous. The removal of <a href="./references#CD000284-bbs2-0037" title="CraneGE . Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs. Agressologie1968;2:209‐18. DeLongSL . Incidence and significance of chlorpromazine‐induced eye changes. Diseases of the Nervous System1968;29:19‐22. GardosG , ColeJO , LaBrieRA . A 12‐year follow‐up study of chronic schizophrenics. Hospital and Community Psychiatry1982;33:983‐4. MandelA , GrossM . Agranulocyctosis and phenothiazines. Diseases of the Nervous System1968;29:32‐6. PrienR , ColeJO . High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health ‐ psychopharmacology research branch collaborative study group. Archives of General Psychiatry1968;18:482‐95. PrienR , DeLongS , ColeJ , LevineJ . Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study. Archives of General Psychiatry1970;23:464‐8. PrienRF , ColeJO , BelkinNF . Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. British Journal of Psychiatry1968;115:679‐86. PrienRF , LevineJ , ColeJO . Indications for high dose chlorpromazine therapy in chronic schizophrenia. Diseases of the Nervous System1970;31:739‐45. ">Prien 1968</a> and <a href="./references#CD000284-bbs2-0050" title="SpohnH , LacoursiereR , ThompsonK , CoyneL . Phenothiazine effects on psychological and psychophysiological dysfunction in chronic schizophrenics. Archives of General Psychiatry1977;34(6):633‐44. ">Spohn 1977</a> did restore homogeneity in the short‐ and medium‐term studies. The <a href="./references#CD000284-bbs2-0037" title="CraneGE . Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs. Agressologie1968;2:209‐18. DeLongSL . Incidence and significance of chlorpromazine‐induced eye changes. Diseases of the Nervous System1968;29:19‐22. GardosG , ColeJO , LaBrieRA . A 12‐year follow‐up study of chronic schizophrenics. Hospital and Community Psychiatry1982;33:983‐4. MandelA , GrossM . Agranulocyctosis and phenothiazines. Diseases of the Nervous System1968;29:32‐6. PrienR , ColeJO . High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health ‐ psychopharmacology research branch collaborative study group. Archives of General Psychiatry1968;18:482‐95. PrienR , DeLongS , ColeJ , LevineJ . Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study. Archives of General Psychiatry1970;23:464‐8. PrienRF , ColeJO , BelkinNF . Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. British Journal of Psychiatry1968;115:679‐86. PrienRF , LevineJ , ColeJO . Indications for high dose chlorpromazine therapy in chronic schizophrenia. Diseases of the Nervous System1970;31:739‐45. ">Prien 1968</a> study was different because of the very large dosages of chlorpromazine that were employed, although it had two arms, one with lower doses and another with higher doses, and these two arms were pooled in the analysis. An 86% efficacy was found for the high‐dose arm in preventing relapse and a 68% efficacy for the low‐dose arm; the confidence intervals only minimally overlap, so there is a potential impact of <a href="./references#CD000284-bbs2-0037" title="CraneGE . Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs. Agressologie1968;2:209‐18. DeLongSL . Incidence and significance of chlorpromazine‐induced eye changes. Diseases of the Nervous System1968;29:19‐22. GardosG , ColeJO , LaBrieRA . A 12‐year follow‐up study of chronic schizophrenics. Hospital and Community Psychiatry1982;33:983‐4. MandelA , GrossM . Agranulocyctosis and phenothiazines. Diseases of the Nervous System1968;29:32‐6. PrienR , ColeJO . High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health ‐ psychopharmacology research branch collaborative study group. Archives of General Psychiatry1968;18:482‐95. PrienR , DeLongS , ColeJ , LevineJ . Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study. Archives of General Psychiatry1970;23:464‐8. PrienRF , ColeJO , BelkinNF . Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. British Journal of Psychiatry1968;115:679‐86. PrienRF , LevineJ , ColeJO . Indications for high dose chlorpromazine therapy in chronic schizophrenia. Diseases of the Nervous System1970;31:739‐45. ">Prien 1968</a> on this outcome. </p> </section> <section id="CD000284-sec-0166"> <h4 class="title">3. Global state</h4> <p>The best‐quality data would need to be reported from six months onwards, and trials only reported on this outcome at short‐ and medium‐term follow‐ups. The efficacy of chlorpromazine for improving global state is 39% for short‐term data and 29% for medium term, but the data are heterogenous. Considering that there was very little antipsychotic treatment that preceded the advent of chlorpromazine, such an efficacy can be considered nothing less than revolutionary for those with very serious mental illnesses. </p> </section> <section id="CD000284-sec-0167"> <h4 class="title">4. Leaving the study early</h4> <p>The finding that using chlorpromazine results in more people staying in the study could be seen as heartening. Perhaps a genuine decrease in the distressing symptoms of schizophrenia leads to an increased concordance with medication despite the unpleasant side effects of this drug. On the other hand, this apparent willingness to comply may be due partly to sedation and hypotension. These effects (the former being linked to emotive terms such as the 'chemical straitjacket') may decrease a person's ability to make his/her own decisions. </p> </section> <section id="CD000284-sec-0168"> <h4 class="title">5. Mental state</h4> <p>In spite of 45 years of research on this benchmark anti‐psychotic treatment, very little can be said from trials regarding its direct effect on mental state in general or specific symptoms of schizophrenia. </p> </section> <section id="CD000284-sec-0169"> <h4 class="title">6. Satisfaction with care</h4> <p>No studies reported on this outcome, so it is not possible to make any conclusions as to participants’ satisfaction with chlorpromazine treatment. </p> </section> <section id="CD000284-sec-0170"> <h4 class="title">7. Behaviour</h4> <p>There are more data regarding behaviour. No difference in the occurrence of behaviour judged to be disturbed or deteriorated was found in both short‐ and medium‐term analyses, but the medium‐term result is based on heterogeneous data (I<sup>2</sup>=90%). Other measures of behaviour 'unchanged' and the modified Rosenthal scale and the Fergus Falls scale did not result in any significant differences. Continuous endpoint data (<a href="./references#CD000284-bbs2-0002" title="BakerJP . A controlled trial of ethylcrotonylurea. British Journal of Psychiatry1959;105:852‐62. ">Baker 1959</a>) derived from the Parkside Behaviour Rating Scale did favour chlorpromazine but there were only seven participants in each group and we can have no real confidence in this finding. </p> </section> <section id="CD000284-sec-0171"> <h4 class="title">8. Adverse effects</h4> <p>Clinicians will not be surprised that chlorpromazine produces acute movement disorders, parkinsonism, fits, tremor, rigidity, weakness and sleepiness. This Cochrane review, however, is a rare report of the best available and quantitative data on this compound that is now over half a century old. Estimates of the incidence of movement disorders such as tardive dyskinesia, however, are not available from this review, as these necessitate a long follow‐up period that was only attempted in a few trials. Evidence supporting a link between chlorpromazine and akathisia is much less convincing than that for acute movement disorders, such as oculogyric crisis, and parkinsonism. This suggests that chlorpromazine may be less potent a cause of this unpleasant adverse effect than other compounds. </p> <p>Taking chlorpromazine commonly causes people to become sleepy. This is an effect that, at times, may be welcomed by clinicians, but not necessarily by those with schizophrenia. Short‐term sedation can be advantageous for clinicians trying to manage people with very disturbed behaviour. Sedation often helps to bring a difficult and dangerous situation under control and gives time for antipsychotic measures to be effective. </p> <p>In addition, chlorpromazine has a tendency to cause other adverse effects such as jaundice, photosensitivity, eye opacities, low blood pressure, constipation, urinary retention, blurred vision and dry mouth. The worrying data regarding eye opacities is all derived from one trial (<a href="./references#CD000284-bbs2-0037" title="CraneGE . Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs. Agressologie1968;2:209‐18. DeLongSL . Incidence and significance of chlorpromazine‐induced eye changes. Diseases of the Nervous System1968;29:19‐22. GardosG , ColeJO , LaBrieRA . A 12‐year follow‐up study of chronic schizophrenics. Hospital and Community Psychiatry1982;33:983‐4. MandelA , GrossM . Agranulocyctosis and phenothiazines. Diseases of the Nervous System1968;29:32‐6. PrienR , ColeJO . High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health ‐ psychopharmacology research branch collaborative study group. Archives of General Psychiatry1968;18:482‐95. PrienR , DeLongS , ColeJ , LevineJ . Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study. Archives of General Psychiatry1970;23:464‐8. PrienRF , ColeJO , BelkinNF . Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. British Journal of Psychiatry1968;115:679‐86. PrienRF , LevineJ , ColeJO . Indications for high dose chlorpromazine therapy in chronic schizophrenia. Diseases of the Nervous System1970;31:739‐45. ">Prien 1968</a>). This large trial, however, used up to two grams of chlorpromazine a day and it is likely that the lower doses more usual in current practice would result in less risk of this adverse effect. Chlorpromazine frequently causes weight increase. </p> </section> <section id="CD000284-sec-0172"> <h4 class="title">9. Cost of care</h4> <p>Again, no studies reported on this outcome, so it is not possible to make any conclusions about the cost of chlorpromazine treatment. </p> </section> <section id="CD000284-sec-0173"> <h4 class="title">10. Subgroup analyses</h4> <p>As was likely from the start, the power to detect a real difference between studies in any one of the subgroup analyses was very low. Only subsets of already limited lists of trials were available. The wide confidence intervals could be hiding true differences in effect between the groups. The only suggestions of statistically significant differences were for acutely ill versus chronically ill for the outcomes of global improvement and behaviour, and for high‐dose versus low‐dose studies (relapse between nine weeks and six months). It is important to remember that this is now a non‐randomised comparison between studies, rather than within a study, and that this is one of many statistical tests that were undertaken on this dataset. Further complicating matters is the fact that the other outcomes within this particular subgroup analysis did not clearly support or refute this difference between high and low doses. <a href="./references#CD000284-bbs2-0037" title="CraneGE . Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs. Agressologie1968;2:209‐18. DeLongSL . Incidence and significance of chlorpromazine‐induced eye changes. Diseases of the Nervous System1968;29:19‐22. GardosG , ColeJO , LaBrieRA . A 12‐year follow‐up study of chronic schizophrenics. Hospital and Community Psychiatry1982;33:983‐4. MandelA , GrossM . Agranulocyctosis and phenothiazines. Diseases of the Nervous System1968;29:32‐6. PrienR , ColeJO . High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health ‐ psychopharmacology research branch collaborative study group. Archives of General Psychiatry1968;18:482‐95. PrienR , DeLongS , ColeJ , LevineJ . Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study. Archives of General Psychiatry1970;23:464‐8. PrienRF , ColeJO , BelkinNF . Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. British Journal of Psychiatry1968;115:679‐86. PrienRF , LevineJ , ColeJO . Indications for high dose chlorpromazine therapy in chronic schizophrenia. Diseases of the Nervous System1970;31:739‐45. ">Prien 1968</a> is an unusual study. Using two grams of chlorpromazine per day would be unacceptable in most situations today, a view supported by some of the findings of this review (n=657, 2 RCTs, RR eye opacities from two grams chlorpromazine per day, 3.09 CI 1.9 to 5.1). </p> </section> </section> <section id="CD000284-sec-0174"> <h3 class="title" id="CD000284-sec-0174">Overall completeness and applicability of evidence</h3> <section id="CD000284-sec-0175"> <h4 class="title">Applicability</h4> <p>The 55 included studies in this version of this review include many people who would be recognisable in everyday practice. There are those with strictly diagnosed illnesses, very likely to suffer from schizophrenia, and people whose illness was diagnosed using less rigorous criteria. The results of the subgroup analyses on diagnostic rigour (see <a href="#CD000284-sec-0126">Effects of interventions</a> section 2.5) also support the assertion that the results are widely applicable. </p> <p>The dose of chlorpromazine in the studies included in this review could be considered high (mean 574.1 mg/day SD 445) but, again, these levels are probably common for people with persistent schizophrenia across the globe. </p> <p>Although the outcomes that have been used in this review are accessible to both clinicians and recipients of care, generalising to treatment in community settings, could be problematic. Most studies were undertaken in hospital, whereas the great majority of people with schizophrenia are in the community. </p> </section> <section id="CD000284-sec-0176"> <h4 class="title">Homogeneity</h4> <p>Some results are difficult, or impossible, to interpret because of heterogeneity. The test for homogeneity is based on I<sup>2</sup> analysis, and is often fairly weak, as the number of studies is small. However, the results of such tests, when statistically significant, suggest caution when adding trial data together. </p> </section> </section> <section id="CD000284-sec-0177"> <h3 class="title" id="CD000284-sec-0177">Quality of the evidence</h3> <p>The quality of the current evidence is very low based on GRADE (<a href="./references#CD000284-bbs2-0418" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359‐83. ">Schünemann 2008</a>). The majority of studies did not report the method of randomisation, and only two trials described method of allocation concealment. Although most studies were reported to be double blind, it was not clear in many whether or not the assessors were blinded to treatment group of participants.  Forty‐eight out of the 55 included studies were rated as high risk of bias for selective reporting. Studies frequently presented both dichotomous and continuous data in graphs, or just reported statistical measures of probability (P values). This often made it impossible to acquire raw data for synthesis. It was also common to use P values as a measure of association between intervention and outcomes instead of showing the strength of the association. Although P values are influenced by the strength of the association, they also depend on the sample size of the groups. It is sometimes possible to extract raw data from P values, but their exact values are needed. In the reviewed studies this was not possible, because they were reported as 'P &lt; 0.05' or 'P &gt; 0.05'. Frequently, continuous data were presented without providing standard deviations or standard errors (33/55 trials) or no data were presented at all (11/55 trials). In this way a lot of potentially informative data were lost. In some studies it seemed that attempts had been made to use the original trials as vehicles for answering a host of other questions about schizophrenia. As a consequence, data from the randomised parts of the studies became buried beneath copious subgroup analyses. </p> </section> <section id="CD000284-sec-0178"> <h3 class="title" id="CD000284-sec-0178">Potential biases in the review process</h3> <section id="CD000284-sec-0179"> <h4 class="title">1. Adding the old to the new</h4> <p>This work includes studies that span nearly five decades of evaluative studies within psychiatry. It is possible that the rigour of these experiments has changed over time, as have the participants and even the formulation of the drug; it was thought that introduction of impurities in early formulations of chlorpromazine led to jaundice. There is some empirical evidence that the quality of schizophrenia trial reporting has not changed much over time (<a href="./references#CD000284-bbs2-0422" title="ThornleyB , AdamsCE . Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ1998;317:1181‐4. ">Thornley 1998</a>) or, if it has changed, it may even have declined (<a href="./references#CD000284-bbs2-0371" title="AhmedI , SoaresK , SeifasR , AdamsCE . Randomised controlled trials in Archives of General Psychiatry (1959‐1995): a prevalence study. Archives of General Psychiatry1998;55(8):754‐5. ">Ahmed 1998</a>). We have found no time‐related differences in reporting of studies within this review and no suggestion of a change of the effect size over time. Synthesis of the results of studies seems justified. </p> </section> <section id="CD000284-sec-0180"> <h4 class="title">2. Failing to identify old trials</h4> <p>We identified trials by meticulous searching, including handsearching old files (2002 update) that covered the drug's development over its first two decades. Nevertheless, for this compound formulated so long ago, publication biases may be difficult to avoid. We did not detect any overt asymmetry of the funnel plots. </p> <p>The strength of this review is that it presents up‐to‐date quantitative data for a benchmark treatment for schizophrenia that is used throughout the world. </p> </section> <section id="CD000284-sec-0181"> <h4 class="title">3. Sensitivity analyses on dishonest researchers</h4> <p>We felt that it would be harsh to immediately delete all trial data associated with Drs Borison and Diamond without empirical data. That removal of their data makes no discernable difference to any outcome is reassuring. </p> </section> </section> <section id="CD000284-sec-0182"> <h3 class="title" id="CD000284-sec-0182">Agreements and disagreements with other studies or reviews</h3> <p>We do not know of any other systematic reviews on this topic.</p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD000284-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD000284-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/full#CD000284-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD000284-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/full#CD000284-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD000284-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/full#CD000284-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 1 Death." data-id="CD000284-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 1 Death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 2 Relapse." data-id="CD000284-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 2 Relapse.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 3 Global state: 1a. No overall improvement (psychiatrist‐rated)." data-id="CD000284-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 3 Global state: 1a. No overall improvement (psychiatrist‐rated). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 4 Global state: 1b. No overall improvement (nurse‐rated)." data-id="CD000284-fig-0007" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 4 Global state: 1b. No overall improvement (nurse‐rated). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 5 Global state: 2. Average endpoint score ‐ short term (CGI, high score=worse)." data-id="CD000284-fig-0008" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 5 Global state: 2. Average endpoint score ‐ short term (CGI, high score=worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 6 Global state: 3a. Severity of illness, severely ill or worse (CGI 5+ points, psychiatrist‐rated)." data-id="CD000284-fig-0009" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 6 Global state: 3a. Severity of illness, severely ill or worse (CGI 5+ points, psychiatrist‐rated). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 7 Global state: 3b. Severity of illness, severely ill or worse ‐ medium term (CGI 5+ points, nurse‐rated)." data-id="CD000284-fig-0010" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 7 Global state: 3b. Severity of illness, severely ill or worse ‐ medium term (CGI 5+ points, nurse‐rated). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 8 Leaving the study early." data-id="CD000284-fig-0011" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 8 Leaving the study early.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 9 Mental state: 1. Improved ‐ short term (BPRS, 50% change)." data-id="CD000284-fig-0012" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 9 Mental state: 1. Improved ‐ short term (BPRS, 50% change). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 10 Mental state: 2. Average endpoint scores (BPRS, high score=worse)." data-id="CD000284-fig-0013" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 10 Mental state: 2. Average endpoint scores (BPRS, high score=worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 11 Behaviour: 1. Deteriorated/ disturbed/un‐cooperative." data-id="CD000284-fig-0014" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 11 Behaviour: 1. Deteriorated/ disturbed/un‐cooperative. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 12 Behaviour: 2. Unchanged." data-id="CD000284-fig-0015" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 12 Behaviour: 2. Unchanged.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 13 Behaviour: 3. Average endpoint scores (RRS, high score=worse)." data-id="CD000284-fig-0016" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 13 Behaviour: 3. Average endpoint scores (RRS, high score=worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 14 Behaviour: 4. Average endpoint score ‐ short term (PBRS, high score=good)." data-id="CD000284-fig-0017" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 14 Behaviour: 4. Average endpoint score ‐ short term (PBRS, high score=good). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 15 Behaviour: 5. Average endpoint scores ‐ medium term (Fergus Falls Behavioural rating scale)." data-id="CD000284-fig-0018" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 15 Behaviour: 5. Average endpoint scores ‐ medium term (Fergus Falls Behavioural rating scale). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 16 Adverse effects: 1. Movement disorders." data-id="CD000284-fig-0019" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 16 Adverse effects: 1. Movement disorders. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 17 Adverse effects: 2. Movement disorders: Average endpoint scores (Extrapyramidal Bilan, high score=worse)." data-id="CD000284-fig-0020" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 17 Adverse effects: 2. Movement disorders: Average endpoint scores (Extrapyramidal Bilan, high score=worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 18 Adverse effects: 1. Central nervous system." data-id="CD000284-fig-0021" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 18 Adverse effects: 1. Central nervous system. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 19 Adverse effects: 3. Blood, skin, liver, eyes." data-id="CD000284-fig-0022" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 19 Adverse effects: 3. Blood, skin, liver, eyes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 20 Adverse effects: 4. Other." data-id="CD000284-fig-0023" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 20 Adverse effects: 4. Other.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 21 SUBGROUP ANALYSIS: 1. MEN vs WOMEN: Behaviour: Deteriorated/disturbed/un‐cooperative." data-id="CD000284-fig-0024" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 21 SUBGROUP ANALYSIS: 1. MEN vs WOMEN: Behaviour: Deteriorated/disturbed/un‐cooperative. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 22 SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC." data-id="CD000284-fig-0025" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 22 SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-CMP-001-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-CMP-001-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 23 SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE." data-id="CD000284-fig-0026" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 23 SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-CMP-001-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-CMP-001-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 24 SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA." data-id="CD000284-fig-0027" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 24 SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-CMP-001-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-CMP-001-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 25 SUBGROUP ANALYSIS: 5. STUDIES PRE‐1990 vs STUDIES 1990‐2007." data-id="CD000284-fig-0028" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 25 SUBGROUP ANALYSIS: 5. STUDIES PRE‐1990 vs STUDIES 1990‐2007. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-CMP-001-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-CMP-001-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 26 SENSITIVITY ANALYSIS: 1. RANDOMISATION." data-id="CD000284-fig-0029" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 26 SENSITIVITY ANALYSIS: 1. RANDOMISATION.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000284-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/urn:x-wiley:14651858:media:CD000284:CD000284-CMP-001-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_t/tCD000284-CMP-001-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 27 SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA." data-id="CD000284-fig-0030" src="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1 CHLORPROMAZINE versus PLACEBO, Outcome 27 SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/media/CDSR/CD000284/image_n/nCD000284-CMP-001-27.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD000284-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">CHLORPROMAZINE versus PLACEBO for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CHLORPROMAZINE versus PLACEBO for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> hospital and community<br/> <b>Intervention:</b> CHLORPROMAZINE versus PLACEBO </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> CHLORPROMAZINE versus PLACEBO</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b> <br/> Follow‐up: 5 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study specifically reported mortality and there were no deaths in either the chlorpromazine or placebo group. There were no reports of death in any other study. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b> <br/> Follow‐up: 6 months to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>710 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>461 per 1000</b> <br/> (334 to 639) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.65</b> <br/> (0.47 to 0.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>512<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 trials report this outcome at 0‐8 weeks follow‐up, 3 trials at 6 months to 2 years, and 2 trials 2‐5 years, none showed a significant difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Global state: no overall improvement</b> <br/> (psychiatrist ‐ rated)<br/> Follow‐up: 9 weeks to 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>897 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>637 per 1000</b> <br/> (520 to 772) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.71</b> (0.58 to 0.90) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1164<br/> (14 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>5,6,7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 trials also reported on this outcome at 0‐8 weeks follow‐up and showed a significant result in favour of chlorpromazine. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leaving the study early</b> <br/> Follow‐up: 9 weeks to 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>128 per 1000</b> <br/> (106 to 156) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.64</b> <br/> (0.53 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1831<br/> (27 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 trials reported on this outcome at 0‐8 weeks follow‐up and showed significant results in favour of chlorpromazine. 2 trials reported on this outcome at 6 months to 2 years follow‐up, and 1 trial at 2‐5 years, and there was no significant difference. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with treatment</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Behaviour: deteriorated/ disturbed/un‐cooperative</b> <br/> Follow‐up: 9 weeks to 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>471 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>231 per 1000</b> <br/> (113 to 471) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.49</b> <br/> (0.24 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1040<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>4,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 trials reported on this outcome at 0‐8 weeks follow‐up and found no significant difference. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cost of care</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Serious risk of bias: the study had an unclear risk of bias for random sequence generation, allocation concealment and other bias as the drugs were provided by a pharmaceutical company.<br/> <sup>2</sup> Very serious imprecision: there are very few participants and no events for this outcome.<br/> <sup>3</sup> Serious risk of bias: all studies had an unclear risk of bias for random sequence generation, allocation concealment, blinding of assessors and incomplete data. One also had an unclear risk of other bias as the drugs were provided by a pharmaceutical company.<br/> <sup>4</sup> Very serious inconsistency: there was very high heterogeneity in the pooled results.<br/> <sup>5</sup> Serious risk of bias: one study had a high risk of bias for random sequence generation and in eleven studies it was unclear. Twelve studies had an unclear risk of bias for allocation concealment. Blinding of participants and personnel was unclear in seven studies and blinding of assessors was unclear in twelve. Four studies also had a high risk of other bias as they were funded by industry.<br/> <sup>6</sup> Serious inconsistency: there was high heterogeneity in the pooled results.<br/> <sup>7</sup> Strongly suspected publication bias: the funnel plot suggests that there may be studies without statistically significant effects that have not been included in this analysis.<br/> <sup>8</sup> Very serious risk of bias: twenty four of the studies had an unclear risk of bias for random sequence generation, and all but one for allocation concealment. Twelve studies had an unclear risk of bias for blinding of participants and personnel and in 23 studies it was unclear whether assessors were blinded. Six studies also had a high risk of other bias as they were partly funded by industry.<br/> <sup>9</sup> Serious risk of bias: all studies had an unclear risk of bias for random sequence generation, and all but one for allocation concealment. Three studies had an unclear risk of bias for blinding of participants and personnel, and in all studies it was unclear whether assessors were blinded. Two studies also had a high risk of other bias as they were partly funded by industry. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">CHLORPROMAZINE versus PLACEBO for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/full#CD000284-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000284-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Mental state: 3. Average BPRS change score (large decline=best)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Chlorpromazine mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Chlorpromazine SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Chlorpromazine N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo N</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000284-bbs2-0018" title="CooperSJ , ButlerA , TweedJ , WelchCP . Zotepine in the treatment of chronic schizophrenia. 10th ECNP (European College of Neuropsychopharmacology) Congress. Vienna, Austria. Vienna, Austria, September 13‐17, 1997. CooperSJ , RaniwallaJ , WelchC . Zotepine in acute exacerbation of schizophrenia: a comparison versus chlorpromazine and placebo. XXth Collegium Internationale Neuro‐psychopharmacologicum. Melbourne, Australia. Melbourne, Australia, 1996. CooperSJ , TweedJ , RaniwallaJ , ButlerA , WelchC . A placebo controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatrica Scandinavica2000;101(3):218‐25. [MEDLINE: 20184895] CooperSJ , TweedJ , RaniwallaJ , WelchC . A placebo‐controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Unpublished manuscript1996. CooperSJ , WelchCP . A comparison of zotepine and chlorpromazine on BPRS subscores. 10th ECNP (European College of Neuropsychopharmacology) Congress. Vienna, Austria. Vienna, Austria, September 13‐17, 1997. ">Cooper 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53 (LOCF)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53 (LOCF)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>LOCF ‐ last observation carried forward</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Mental state: 3. Average BPRS change score (large decline=best)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/full#CD000284-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000284-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">CHLORPROMAZINE versus PLACEBO</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 short term (0‐8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.01, 5.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 medium term (9 weeks ‐ 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>809</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.21, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 long term (6 months ‐ 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.47, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 2 ‐ 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.51, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global state: 1a. No overall improvement (psychiatrist‐rated) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 short term (0‐8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>728</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.46, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 medium term (9 weeks ‐ 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.58, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Global state: 1b. No overall improvement (nurse‐rated) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 short term (0‐8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.65, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 medium term (9 weeks‐6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.35, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Global state: 2. Average endpoint score ‐ short term (CGI, high score=worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.35, 0.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Global state: 3a. Severity of illness, severely ill or worse (CGI 5+ points, psychiatrist‐rated) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 short term (0‐8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.16, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 medium term (9 weeks ‐ 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>694</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.74, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Global state: 3b. Severity of illness, severely ill or worse ‐ medium term (CGI 5+ points, nurse‐rated) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.45, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 short term (0‐8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1065</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.63, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 medium term (9 weeks ‐ 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1831</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.53, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 long term (&gt;6 months ‐ 2 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>492</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.71, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 &gt;2 ‐ 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.35, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mental state: 1. Improved ‐ short term (BPRS, 50% change) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.36, 4.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Mental state: 2. Average endpoint scores (BPRS, high score=worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 short term (0‐8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.82 [‐8.48, ‐1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 medium term (9 weeks ‐ 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.70 [‐14.77, ‐0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Behaviour: 1. Deteriorated/ disturbed/un‐cooperative <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 short term ‐ (0‐8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.34, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 medium term (9 weeks ‐ 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1040</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.24, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Behaviour: 2. Unchanged <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 short term (0‐8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.25, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 medium term (9 weeks ‐ 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.64, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Behaviour: 3. Average endpoint scores (RRS, high score=worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 short term (0‐8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.90 [‐6.74, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 medium term (9 weeks ‐ 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.60 [‐9.47, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Behaviour: 4. Average endpoint score ‐ short term (PBRS, high score=good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.0 [1.97, 10.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Behaviour: 5. Average endpoint scores ‐ medium term (Fergus Falls Behavioural rating scale) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.36 [‐6.11, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse effects: 1. Movement disorders <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 acute movement disorders (dystonia)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>942</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.47 [1.50, 8.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 parkinsonism (includes EPS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.11 [1.59, 2.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [1.01, 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 rigidity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.24 [1.42, 3.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.5 akathisia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.54, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.6 chronic movement disorders (tardive dyskinesia)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.32, 6.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.7 ataxia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.64 [0.94, 79.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse effects: 2. Movement disorders: Average endpoint scores (Extrapyramidal Bilan, high score=worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 short term (0‐8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.40 [‐3.22, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 medium term (9 weeks ‐ 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.80 [‐4.19, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Adverse effects: 1. Central nervous system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 sleepiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1627</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.79 [2.25, 3.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 fits / loss of consciousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.11 [1.05, 9.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 weakness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.33 [1.02, 10.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4 convulsions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Adverse effects: 3. Blood, skin, liver, eyes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 blood problems (agranulocytosis, leukopenia)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.08 [0.74, 5.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 rashes/itching/skin disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.92, 2.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3 liver problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.31 [0.98, 18.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.4 photosensitivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>799</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.04 [3.22, 11.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.5 eye opacity / eye pigment problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>657</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.09 [1.87, 5.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Adverse effects: 4. Other <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 blood pressure ‐ low +/‐ dizziness/syncope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1488</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.38 [1.74, 3.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [1.33, 3.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3 urinary problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>926</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.70, 4.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.4 blurred vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>962</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.51, 2.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.5 dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.56 [2.35, 8.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.6 weight increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.92 [2.32, 10.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.7 weight decrease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.22, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.8 nausea/vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1024</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.07 [1.14, 3.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.9 salivation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>830</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.37 [1.07, 10.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.10 menorrhagia / abnormal menstruation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.62, 3.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.11 amenorrhea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.17, 3.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.12 lactation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.57, 3.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 SUBGROUP ANALYSIS: 1. MEN vs WOMEN: Behaviour: Deteriorated/disturbed/un‐cooperative <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 only men</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.00, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 only women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.29, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 SUBGROUP ANALYSIS: 2. ACUTE vs CHRONIC <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 acute ‐ Relapse (9 wks ‐ 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.94, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 chronic ‐ Relapse (9 wks ‐ 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>682</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.18, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3 acute ‐ Global state 1. No overall improvement (0‐8 wks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.44, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.4 chronic ‐ Global state 1. No overall improvement (0‐8 wks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.39, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.5 acute ‐ Global state 2. No overall improvement (9 wks‐6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.03, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.6 chronic ‐ Global state 2. No overall improvement (9 wks‐6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.64, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.7 acute ‐ Behaviour deteriorated/disturbed/unco‐operative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.60, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.8 chronic ‐ Behaviour deteriorated/disturbed/unco‐operative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.26, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 SUBGROUP ANALYSIS: 3. HIGH vs LOW DOSE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 high ‐ Relapse (9 wks‐6 Months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.08, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 low ‐ Relapse (9 wks‐6 Months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.26, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.3 high ‐ Global state 1. No overall improvement (0‐8 wks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.18, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.4 low ‐ Global state 1. No overall improvement (0‐8 wks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.52, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.5 high ‐ Global state 1. No overall improvement (9 wks‐6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.51, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.6 low ‐ Global state 1. No overall improvement (9 wks‐6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>493</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.60, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.7 high ‐ Behaviour 1. Deteriorated/disturbed/unco‐operative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>447</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.04, 6.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.8 low ‐ Behaviour 1. Deteriorated/disturbed/unco‐operative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.27, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 SUBGROUP ANALYSIS: 4. DIAGNOSTIC CRITERIA vs NO DIAGNOSTIC CRITERIA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 diagnostic criteria ‐ Relapse (0‐8 wks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.26, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 no diagnostic criteria ‐ Relapse (0‐8 wks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.00, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.3 diagnostic criteria ‐ Relapse (9 wks‐6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>662</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.13, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.4 no diagnostic criteria ‐ Relapse (9 wks‐6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.66, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.5 diagnostic criteria ‐ Global state 1. No overall improvement (0‐8 wks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.40, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.6 no diagnostic criteria ‐ Global state 1. No overall improvement (0‐8 wks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>565</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.46, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.7 diagnostic criteria ‐ Global state 1. No overall improvement (9 wks‐6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>689</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.57, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.8 no diagnostic criteria ‐ Global state 1. No overall improvement (9 wks‐6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.59, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.9 diagnostic criteria ‐ Global state 3. Severity of illness (9 wks‐6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.75, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.10 no diagnostic criteria ‐ Global state 3. Severity of illness (9 wks‐6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.36, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.11 diagnostic criteria ‐ Behaviour 1. deteriorated/disturbed/unco‐operative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>670</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.14, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.12 no diagnostic criteria ‐ Behaviour 1. deteriorated/disturbed/unco‐operative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.33, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 SUBGROUP ANALYSIS: 5. STUDIES PRE‐1990 vs STUDIES 1990‐2007 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 Pre‐1990 ‐ Global state 1. No overall improvement (0‐8 wks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>555</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.46, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 1990 to 2002 ‐ Global state 1. No overall improvement (0‐8 wks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.40, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.3 Pre‐1990 ‐ Global state 1. No overall improvement (9 wks‐6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.67, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.4 1990 to 2002 ‐ Global state 1. No overall improvement (9 wks‐6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.30, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.5 Pre‐1990 ‐ Behaviour 1. deteriorated/disturbed/unco‐operative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.26, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.6 1990 to 2002 ‐ Behaviour 1. deteriorated/disturbed/unco‐operative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.60, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 SENSITIVITY ANALYSIS: 1. RANDOMISATION <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 not stated ‐ Global state: 1. No overall improvement (9 weeks ‐ 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.30, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2 stated ‐ Global state: 1. No overall improvement (9 weeks ‐ 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.75, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 SENSITIVITY ANALYSIS: 2. ASSUMPTIONS FOR LOST BINARY DATA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 LOCF ‐ Global state: 1. No overall improvement (0‐8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.17, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 not LOCF ‐ Global state: 1. No overall improvement (0‐8 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>671</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.49, 0.88]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">CHLORPROMAZINE versus PLACEBO</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000284.pub3/references#CD000284-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD000284.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD000284-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD000284-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD000284-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD000284-note-0001">Hrvatski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000284\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000284\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000284\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000284\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000284\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000284\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000284\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000284\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000284\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000284\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000284\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000284\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000284\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000284\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000284\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000284\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000284\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000284\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000284.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000284.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD000284.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD000284.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000284.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715927642"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000284.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715927646"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000284.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d93019a939368',t:'MTc0MDcxNTkyNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 